{"protocolSection":{"identificationModule":{"nctId":"NCT02409342","orgStudyIdInfo":{"id":"GO29431"},"secondaryIdInfos":[{"id":"2014-003083-21","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]","officialTitle":"A Phase III, Open Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With a Platinum Agent (Cisplatin or Carboplatin) in Combination With Either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naive Patients With Stage IV Non-Squamous Or Squamous Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2023-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-07-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-02-04","type":"ACTUAL"},"completionDateStruct":{"date":"2022-03-08","type":"ACTUAL"},"studyFirstSubmitDate":"2015-04-01","studyFirstSubmitQcDate":"2015-04-01","studyFirstPostDateStruct":{"date":"2015-04-06","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-01-26","resultsFirstSubmitQcDate":"2021-01-26","resultsFirstPostDateStruct":{"date":"2021-02-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-02-17","lastUpdatePostDateStruct":{"date":"2023-03-15","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This randomized, open-label study will evaluate the efficacy and safety of atezolizumab compared with chemotherapy consisting of a platinum agent (cisplatin or carboplatin per investigator discretion) combined with either pemetrexed (non-squamous disease) or gemcitabine (squamous disease) in programmed death-ligand 1 (PD-L1)-selected, chemotherapy-naive participants with Stage IV Non-Squamous or Squamous NSCLC."},"conditionsModule":{"conditions":["Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":572,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"(Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","type":"ACTIVE_COMPARATOR","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months). Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).","interventionNames":["Drug: Carboplatin","Drug: Cisplatin","Drug: Gemcitabine","Drug: Pemetrexed"]},{"label":"Atezolizumab","type":"EXPERIMENTAL","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).","interventionNames":["Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody"]}],"interventions":[{"type":"DRUG","name":"Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody","description":"Atezolizumab 1200 milligram (mg) will be administered as intravenous infusion every 21 days until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).","armGroupLabels":["Atezolizumab"],"otherNames":["MPDL3280A, RO5541267"]},{"type":"DRUG","name":"Carboplatin","description":"Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) 6 when given in combination with pemetrexed or at a dose of AUC 5 when given in combination with gemcitabine, every 21 days for 4 or 6 cycles as per local standard of care.","armGroupLabels":["(Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)"]},{"type":"DRUG","name":"Cisplatin","description":"Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (mg/m\\^2) every 21 days for 4 or 6 cycles as per local standard of care.","armGroupLabels":["(Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)"]},{"type":"DRUG","name":"Gemcitabine","description":"Gemcitabine will be administered as intravenous infusion at a dose of 1250 mg/m\\^2 (in combination with cisplatin) or 1000 mg/m\\^2 (in combination with carboplatin), on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles as per local standard of care.","armGroupLabels":["(Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)"]},{"type":"DRUG","name":"Pemetrexed","description":"Pemetrexed will be administered as intravenous infusion at a dose of 500 mg/m\\^2 on Day 1 of each 21-day cycle as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).","armGroupLabels":["(Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Survival (OS) in the TC3 or IC3-WT Populations","description":"OS is defined as the time from randomization to death from any cause.","timeFrame":"From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months)"},{"measure":"Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations","description":"OS is defined as the time from randomization to death from any cause.","timeFrame":"From randomization to death from any cause until data cut-off on 4 February 2020 (up to approximately 54.5 months)"}],"secondaryOutcomes":[{"measure":"Progression-free Survival (PFS) in the TC3 or IC3-WT Populations","description":"PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first. PFS could not be formally tested.","timeFrame":"From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)"},{"measure":"Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations","description":"PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first. PFS could not be formally tested.","timeFrame":"From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 4 February 2020 (up to approximately 54.5 months)"},{"measure":"Percentage of Participants With Objective Response (ORR) in the TC3 or IC3-WT Populations","description":"Objective response (partial response plus complete response) as determined by the investigator according to RECIST v1.1.","timeFrame":"Every 6 weeks for 48 weeks following Day 1, thereafter every 9 weeks after completion of Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression until data cut-off on 10 Sep 2018 (up to approximately 38 months)"},{"measure":"Percentage of Participants With Objective Response (ORR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations","description":"Objective response (partial response plus complete response) as determined by the investigator according to RECIST v1.1.","timeFrame":"Every 6 weeks for 48 weeks following Day 1, thereafter every 9 weeks after completion of Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression until data cut-off on 4 Feb 2020 (up to approximately 54.5 months)"},{"measure":"Duration of Response (DOR) in the TC3 or IC3-WT Populations","description":"DOR is defined as the time from the first occurrence of a documented objective response to the time of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first.","timeFrame":"From first occurrence of a complete response or partial response, whichever occurs first, until first date that progressive disease or death is documented, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)"},{"measure":"Duration of Response (DOR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations","description":"DOR is defined as the time from the first occurrence of a documented objective response to the time of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first.","timeFrame":"From first occurrence of a complete response or partial response, whichever occurs first, until first date that progressive disease or death is documented, whichever occurs first until data cut-off on 4 February 2020 (up to approximately 54.5 months)"},{"measure":"Percentage of Participants Who Are Alive at 1 Year in the TC3 or IC3-WT Populations","timeFrame":"Baseline to 1 year or death, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)"},{"measure":"Percentage of Participants Who Are Alive at 2 Years in the TC3 or IC3-WT Populations","timeFrame":"Baseline to 2 years or death, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)"},{"measure":"Percentage of Participants Who Are Alive at 1 Year in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations","timeFrame":"Baseline to 1 year or death, whichever occurs first until clinical cut-off date on 4 February 2020 (up to approximately 54.5 months)"},{"measure":"Percentage of Participants Who Are Alive at 2 Years in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations","timeFrame":"Baseline to 2 years or death, whichever occurs first until clinical cut-off date on 4 February 2020 (up to approximately 54.5 months)"},{"measure":"Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Score as Assessed by the Symptoms in Lung Cancer (SILC) Scale Symptom Score in the TC3 or IC3-WT Populations","description":"TTD in each of the patient-reported lung cancer symptoms with use of the SILC scale. The SILC scale is a nine-item content valid self-report measure of lung cancer symptoms. It measures severity of cough, dyspnea, and chest pain with a total symptom severity score. Each SILC symptom scale (dyspnea, cough, chest pain) score was calculated as the average of the component items (range 0 to 4). An increase in score suggested worsening in symptomatology. A symptom score change of 0.3 points for the dyspnea and cough scores was considered to be clinically significant; whereas a symptom score change of 0.5 points for the chest pain score was considered to be clinically significant.","timeFrame":"Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)"},{"measure":"Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations","description":"Change from baseline in each of the patient-reported lung cancer symptoms with use of the SILC scale. The SILC scale is a nine-item content valid self-report measure of lung cancer symptoms. It measures severity of cough, dyspnea, and chest pain with a total symptom severity score. Each SILC symptom scale (dyspnea, cough, chest pain) score was calculated as the average of the component items (range 0 to 4). An increase in score suggested worsening in symptomatology. A symptom score change of 0.3 points for the dyspnea and cough scores was considered to be clinically significant; whereas a symptom score change of 0.5 points for the chest pain score was considered to be clinically significant.","timeFrame":"Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)"},{"measure":"TTD as Assessed Using EORTC QLQ Supplementary Lung Cancer Module (EORTC QLQ-LC13) in the TC3 or IC3-WT Populations","description":"TTD in patient-reported lung cancer symptoms, defined as time from randomization to deterioration (10-point change) in any of the following symptom subscales (cough, dyspnea \\[multi-item scale\\], and chest pain), whichever occurs first, as measured by the EORTC QLQ-LC13. EORTC QLQ-LC13 module incorporates one multi-item scale to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis.","timeFrame":"Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)"},{"measure":"OS in Participants With PD-L1 Expression","description":"OS is defined as the time from randomization to death from any cause.","timeFrame":"From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months)"},{"measure":"Investigator-Assessed PFS in Participants With PD-L1 Expression According to RECIST v1.1","description":"Investigator-assessed PFS according to RECIST v1.1 in the PD-L1 (defined with SP263 IHC assay)","timeFrame":"From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)"},{"measure":"OS in Participants With Blood Tumor Mutational Burden (bTMB)","description":"OS is defined as the time from randomization to death from any cause.","timeFrame":"From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months)"},{"measure":"Investigator-Assessed PFS in Participants With bTMB According to RECIST v1.1","description":"PFS according to RECIST v1.1 in the bTMB subpopulations.","timeFrame":"From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)"},{"measure":"Minimum Observed Serum Concentration (Cmin) of Atezolizumab","timeFrame":"Prior to infusion (0 hour) on Day 1 of Cycles 2, 3, 4, 8, 16, and every eighth cycle thereafter, and at treatment discontinuation until data cut-off on 10 September 2018 (up to approximately 38 months) (cycle duration = 21 days)"},{"measure":"Maximum Observed Serum Concentration (Cmax) of Atezolizumab","timeFrame":"0 hour (predose) and 30 minutes after atezolizumab infusion on Day 1 (infusion duration = up to 1 hour)"},{"measure":"Percentage of Participants With at Least One Adverse Event","description":"Percentage of participants with at least one adverse event.","timeFrame":"Baseline up to until data cut-off on 8 March 2022 (up to approximately 79.5 months)"},{"measure":"Percentage of Participants With Anti-therapeutic Antibodies (ATAs)","timeFrame":"Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed, Stage IV non-squamous or squamous NSCLC\n* No prior treatment for Stage IV non-squamous or squamous NSCLC. Participant known to have a sensitizing mutation in the epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) fusion oncogene are excluded from the study\n* Tumor PD-L1 expression as determined by immunohistochemistry (IHC) assay of archival tumor tissue or tissue obtained at screening\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1\n* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)\n* Adequate hematologic and end-organ function\n\nExclusion Criteria:\n\n* Known sensitizing mutation in the EGFR gene or ALK fusion oncogene\n* Active or untreated central nervous system (CNS) metastases as determined by Computed Tomography (CT) or magnetic resonance imaging (MRI) evaluation\n* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome\n* Pregnant or lactating women\n* History of autoimmune disease\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted\n* Positive test for Human Immunodeficiency Virus (HIV)\n* Active hepatitis B or hepatitis C\n* Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint blockade therapies, anti PD1, and anti-PD-L1 therapeutic antibody\n* Severe infection within 4 weeks prior to randomization\n* Significant history of cardiovascular disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"University of California San Diego","city":"La Jolla","state":"California","zip":"92093","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Yale Cancer Center","city":"New Haven","state":"Connecticut","zip":"06520","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Lynn Cancer Institute - West","city":"Boca Raton","state":"Florida","zip":"33428","country":"United States","geoPoint":{"lat":26.35869,"lon":-80.0831}},{"facility":"University of Maryland Greenebaum Cancer Center","city":"Baltimore","state":"Maryland","zip":"21201","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Oregon Health & Science Uni","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Sarah Cannon Cancer Center","city":"Germantown","state":"Tennessee","zip":"38138","country":"United States","geoPoint":{"lat":35.08676,"lon":-89.81009}},{"facility":"Vanderbilt University Medical Center; Multiple Sclerosis Center","city":"Nashville","state":"Tennessee","zip":"37204","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Hematology Oncology Associates of Fredericksburg, Inc.","city":"Fredericksburg","state":"Virginia","zip":"22408","country":"United States","geoPoint":{"lat":38.30318,"lon":-77.46054}},{"facility":"VA Puget Sound Health Care Sys","city":"Seattle","state":"Washington","zip":"98108","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Centro de Pesquisas Clinicas em Oncologia - CPCO","city":"Cachoeiro de Itapemirim","state":"Espírito Santo","zip":"29308-014","country":"Brazil","geoPoint":{"lat":-20.84889,"lon":-41.11278}},{"facility":"Oncovida*X","city":"Salvador","state":"Estado de Bahia","zip":"41820-021","country":"Brazil","geoPoint":{"lat":-12.97563,"lon":-38.49096}},{"facility":"Instituto Nacional de Cancer - INCa; Oncologia","city":"Rio de Janeiro","state":"Rio de Janeiro","zip":"20560-120","country":"Brazil","geoPoint":{"lat":-22.90642,"lon":-43.18223}},{"facility":"Associacao Hospital de Caridade Ijui*X; Departamento De Oncologia","city":"Ijuí","state":"Rio Grande do Sul","zip":"98700-000","country":"Brazil","geoPoint":{"lat":-28.38778,"lon":-53.91472}},{"facility":"Hospital da Cidade de Passo Fundo; Centro de Pesquisa em Oncologia","city":"Passo Fundo","state":"Rio Grande do Sul","zip":"99010-260","country":"Brazil","geoPoint":{"lat":-28.26278,"lon":-52.40667}},{"facility":"Santa Casa de Misericordia de Porto Alegre","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"90020-090","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Hospital Sao Lucas - PUCRS","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"90610-000","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Instituto Joinvilense de Hematologia E Oncologia","city":"Joinville","state":"Santa Catarina","zip":"89201-260","country":"Brazil","geoPoint":{"lat":-26.30444,"lon":-48.84556}},{"facility":"*X*Fundacao PIO XII","city":"Barretos","state":"São Paulo","zip":"14784-400","country":"Brazil","geoPoint":{"lat":-20.55722,"lon":-48.56778}},{"facility":"Instituto Do Câncer Do Estado de São Paulo Octávio Frias de Oliveira","city":"São Paulo","state":"São Paulo","zip":"01246 000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Hospital Santa Marcelina","city":"São Paulo","state":"São Paulo","zip":"08270-070","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Harbin Medical University Tumor Hospital","city":"Harbin","zip":"150081","country":"China","geoPoint":{"lat":45.75,"lon":126.65}},{"facility":"CHU Angers","city":"Angers","zip":"49933","country":"France","geoPoint":{"lat":47.47156,"lon":-0.55202}},{"facility":"Hospital d Instructions des Armees Percy","city":"Clamart","zip":"92141","country":"France","geoPoint":{"lat":48.80299,"lon":2.26692}},{"facility":"Hôpital Universitaire Dupuytren","city":"Limoges","zip":"87042","country":"France","geoPoint":{"lat":45.83362,"lon":1.24759}},{"facility":"Clinique Clémentville","city":"Montpellier","zip":"34070","country":"France","geoPoint":{"lat":43.61093,"lon":3.87635}},{"facility":"Centre D'oncologie de Gentilly","city":"Nancy","zip":"54100","country":"France","geoPoint":{"lat":48.68439,"lon":6.18496}},{"facility":"Hopital Tenon","city":"Paris","zip":"75020","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Centre Hospitalier Regional La Reunion Site Felix Guyon","city":"Saint-Denis","zip":"97405","country":"France","geoPoint":{"lat":48.93564,"lon":2.35387}},{"facility":"Hopital d'Instruction des Armees de Begin","city":"Saint-Mandé","zip":"94160","country":"France","geoPoint":{"lat":48.83864,"lon":2.41579}},{"facility":"Centre Hospitalier Regional Sud Reunion","city":"Saint-Pierre","zip":"97448","country":"France","geoPoint":{"lat":43.29282,"lon":5.40682}},{"facility":"Centre Paul Strauss","city":"Strasbourg","zip":"67000","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"Asklepios-Fachklinik Muenchen-Gauting; Klinik Für Pneumologie","city":"Gauting","zip":"82131","country":"Germany","geoPoint":{"lat":48.06919,"lon":11.37703}},{"facility":"Pius-Hospital Oldenburg","city":"Oldenburg","zip":"26121","country":"Germany","geoPoint":{"lat":53.14118,"lon":8.21467}},{"facility":"Sotiria Chest Hospital of Athens","city":"Athens","zip":"11527","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"IASO General Hospital of Athens","city":"Athens","zip":"155 62","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"Metropolitan Hospital","city":"Athens","zip":"185 47","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"Attikon University General Hospital","city":"Chaïdári","zip":"124 62","country":"Greece","geoPoint":{"lat":38.01135,"lon":23.66597}},{"facility":"University General Hospital of Larissa","city":"Larissa","zip":"412 21","country":"Greece","geoPoint":{"lat":39.62847,"lon":22.42112}},{"facility":"University General Hospital of Patras","city":"Pátrai","zip":"265 00","country":"Greece","geoPoint":{"lat":38.2462,"lon":21.73508}},{"facility":"Thermi Clinic","city":"Thermi, Thessaloniki","zip":"57001","country":"Greece"},{"facility":"Bioclinic Thessaloniki","city":"Thessaloniki","zip":"546 22","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"EUROMEDICA General Clinic of Thessaloniki; Gastroenterology Department","city":"Thessaloniki","zip":"54645","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"Papageorgiou General Hospital of Thessaloniki","city":"Thessaloniki","zip":"564 29","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"Georgios Papanikolaou General Hosp. of Thessaloniki","city":"Thessaloniki","zip":"57010","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"Uzsoki Utcai Korhaz","city":"Budapest","zip":"1145","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Szabolcs-Szatmar-Bereg Megyei; Korhazak es Egyetemi Oktatokorhaz","city":"Nyíregyháza","zip":"4400","country":"Hungary","geoPoint":{"lat":47.95539,"lon":21.71671}},{"facility":"Pecsi Tudomanyegyetem","city":"Pécs","zip":"7624","country":"Hungary","geoPoint":{"lat":46.07617,"lon":18.22814}},{"facility":"Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet; Megyei Onkologiai Kozpont","city":"Szolnok","zip":"5004","country":"Hungary","geoPoint":{"lat":47.18066,"lon":20.19835}},{"facility":"IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica","city":"Meldola","state":"Emilia-Romagna","zip":"47014","country":"Italy","geoPoint":{"lat":44.12775,"lon":12.0626}},{"facility":"Centro Di Riferimento Oncologico; Struttura Operativa Complessa Di Oncologia Medica B","city":"Aviano","state":"Friuli Venezia Giulia","zip":"33081","country":"Italy","geoPoint":{"lat":46.07056,"lon":12.59472}},{"facility":"Asst Papa Giovanni XXIII","city":"Bergamo","state":"Lombardy","zip":"24100","country":"Italy","geoPoint":{"lat":45.69601,"lon":9.66721}},{"facility":"Azienda Ospedaliera Istituti Ospitalieri","city":"Cremona","state":"Lombardy","zip":"26100","country":"Italy","geoPoint":{"lat":45.13325,"lon":10.02129}},{"facility":"Ospedale San Raffaele S.r.l.","city":"Milan","state":"Lombardy","zip":"20132","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"Istituto Europeo Di Oncologia","city":"Milan","state":"Lombardy","zip":"20141","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"Azienda Socio Sanitaria Territoriale ? ASST di Monza","city":"Monza","state":"Lombardy","zip":"20052","country":"Italy","geoPoint":{"lat":45.58005,"lon":9.27246}},{"facility":"Istituto Nazionale dei Tumori","city":"Monza","state":"Lombardy","zip":"20052","country":"Italy","geoPoint":{"lat":45.58005,"lon":9.27246}},{"facility":"Istituto Clinico Humanitas","city":"Rozzano (MI)","state":"Lombardy","zip":"20089","country":"Italy","geoPoint":{"lat":45.38193,"lon":9.1559}},{"facility":"Azienda Ospedaliera Città della Salute e della Scienza di Torino","city":"Turin","state":"Piedmont","zip":"10126","country":"Italy","geoPoint":{"lat":45.07049,"lon":7.68682}},{"facility":"Azienda Ospedaliero-Universitaria ?PoliclinicoVittorio Emanuele?- P.O. G. Rodolico; Oncologia Medica","city":"Catania","state":"Sicily","zip":"95123","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"facility":"Azienda Ospedaliera Universitaria Integrata Verona; UOC Oncologia","city":"Verona","state":"Veneto","zip":"37126","country":"Italy","geoPoint":{"lat":45.43854,"lon":10.9938}},{"facility":"Aichi Cancer Center Hospital; Respiratory Medicine","city":"Aichi","zip":"464-8681","country":"Japan","geoPoint":{"lat":32.51879,"lon":130.62158}},{"facility":"Nagoya University Hospital; Respiratory Medicine","city":"Aichi","zip":"466-8560","country":"Japan","geoPoint":{"lat":32.51879,"lon":130.62158}},{"facility":"Kyushu University Hospital; Respiratory","city":"Fukuoka","zip":"812-8582","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Hokkaido University Hospital","city":"Hokkaido","zip":"060-8648","country":"Japan"},{"facility":"Kobe City Medical Center General Hospital; Respiratory Medicine","city":"Hyōgo","zip":"650-0047","country":"Japan","geoPoint":{"lat":43.36667,"lon":144.43333}},{"facility":"Hyogo Cancer Center; Thoracic Oncology","city":"Hyōgo","zip":"673-8558","country":"Japan","geoPoint":{"lat":43.36667,"lon":144.43333}},{"facility":"Ibaraki Prefectural Central Hospital; Division of respiratory","city":"Ibaraki","zip":"309-1793","country":"Japan","geoPoint":{"lat":34.81641,"lon":135.56828}},{"facility":"Sendai Kousei Hospital; Pulmonary Medicine","city":"Miyagi","zip":"980-0873","country":"Japan","geoPoint":{"lat":26.62566,"lon":128.18236}},{"facility":"Okayama University Hospital; Respiratory and Allergy Medicine","city":"Okayama","zip":"700-8558","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"Osaka International Cancer Institute; Thoracic Oncology","city":"Osaka","zip":"541-8567","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Kansai Medical university Hospital; Thoracic Oncology","city":"Osaka","zip":"573-1191","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Osaka Habikino Medical Center","city":"Osaka","zip":"583-8588","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"National Hospital Organization Kinki-Chuo Chest Medical Center","city":"Sakaishi","zip":"591-8555","country":"Japan","geoPoint":{"lat":33.41239,"lon":132.71218}},{"facility":"Saitama Cancer Center; Thoracic Oncology","city":"Satima","zip":"362-0806","country":"Japan"},{"facility":"National Cancer Center Hospital; Thoracic Medical Oncology","city":"Tokyo","zip":"104-0045","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Tokyo Medical University Hospital; Dept of Surgery","city":"Tokyo","zip":"160-0023","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Uniwersyteckie Centrum Kliniczne","city":"Gdansk","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie; Oddzial onkologii z pododdzialem chemioterapii","city":"Olsztyn","zip":"10-357","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy","city":"Otwock","zip":"05-400","country":"Poland","geoPoint":{"lat":52.10577,"lon":21.26129}},{"facility":"Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu","city":"Poznan","zip":"60-569","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Med-Polonia Sp. z o.o.","city":"Poznan","zip":"60-693","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Teo Health SA - Saint Constantin Hospital","city":"Brasov","zip":"500091","country":"Romania","geoPoint":{"lat":45.64861,"lon":25.60613}},{"facility":"Prof. Dr. I. Chiricuta Institute of Oncology","city":"Cluj-Napoca","zip":"400015","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"Oncology Center Sf. Nectarie","city":"Craiova","zip":"200347","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"Institutul Regional de Oncologie Iasi; Clinica de Hematologie","city":"Iași","zip":"700483","country":"Romania","geoPoint":{"lat":47.16667,"lon":27.6}},{"facility":"Sibiu Emergency Clinical County Hospital","city":"Sibiu","zip":"550245","country":"Romania","geoPoint":{"lat":45.8,"lon":24.15}},{"facility":"Oncocenter Clinical Oncology","city":"Timi?oara","zip":"300210","country":"Romania"},{"facility":"Oncomed SRL","city":"Timișoara","zip":"300239","country":"Romania","geoPoint":{"lat":45.75372,"lon":21.22571}},{"facility":"Arkhangelsk Regional Clinical Oncology Dispensary","city":"Arkhangelsk","state":"Arhangelsk","zip":"163045","country":"Russia","geoPoint":{"lat":64.5461,"lon":40.55183}},{"facility":"Federal State Institution Medical Radiology Research Center","city":"Obninsk","state":"Kaluga Oblast","zip":"249036","country":"Russia","geoPoint":{"lat":55.10993,"lon":36.61238}},{"facility":"Moscow City Oncology Hospital #62","city":"Moscovskaya Oblast","state":"Moscow Oblast","zip":"143423","country":"Russia"},{"facility":"Principal Military Clinical Hospital n.a. N.N. Burdenko","city":"Moscow","state":"Moscow Oblast","zip":"105229","country":"Russia"},{"facility":"Saint Petersburg Clinical Hospital of the Russian Academy of Sciences","city":"Saint Petersburg","state":"Sankt-Peterburg","zip":"194017","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic","city":"Kazan'","state":"Tatarstan Republic","zip":"420029","country":"Russia","geoPoint":{"lat":55.78874,"lon":49.12214}},{"facility":"Regional Clinical Oncology Center","city":"Ryazan","zip":"390046","country":"Russia","geoPoint":{"lat":54.62696,"lon":39.70415}},{"facility":"Leningrad Regional Clinical Hospital","city":"Saint Petersburg","zip":"194291","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"St. Petersburg Med Univ; n.a. I.P. Pavlov; Pulmonology Research","city":"Saint Petersburg","zip":"197089","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Mordovia State University","city":"Saransk","zip":"430032","country":"Russia","geoPoint":{"lat":54.18485,"lon":45.17166}},{"facility":"Volgograd Regional Clinical Oncology Dispensary","city":"Volgograd","zip":"400138","country":"Russia","geoPoint":{"lat":48.71378,"lon":44.4976}},{"facility":"Clinical Center of Serbia","city":"Belgrade","zip":"11000","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Institute for Oncology and Radiology of Serbia; Medical Oncology","city":"Belgrade","zip":"11000","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Institute of Lung Diseases Vojvodina","city":"Kamenitz","zip":"21204","country":"Serbia","geoPoint":{"lat":45.22334,"lon":19.84263}},{"facility":"Clinical Center Kragujevac","city":"Kragujevac","zip":"34000","country":"Serbia","geoPoint":{"lat":44.01667,"lon":20.91667}},{"facility":"Chonnam National University Hwasun Hospital","city":"Jeollanam-do","zip":"58128","country":"South Korea"},{"facility":"Seoul National University Bundang Hospital","city":"Seongnam-si","zip":"13620","country":"South Korea","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Kangbuk Samsung Hospital","city":"Seoul","zip":"03181","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Hospital Universitario Son Espases","city":"Palma de Mallorca","state":"Balearic Islands","zip":"07010","country":"Spain","geoPoint":{"lat":39.56939,"lon":2.65024}},{"facility":"Hospital Son Llatzer","city":"Palma de Mallorca","state":"Balearic Islands","zip":"07198","country":"Spain","geoPoint":{"lat":39.56939,"lon":2.65024}},{"facility":"Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia","city":"Badalona","state":"Barcelona","zip":"08916","country":"Spain","geoPoint":{"lat":41.45004,"lon":2.24741}},{"facility":"Consorcio Hospitalario Provincial de Castellon","city":"Castellon de LA Plana/castello de LA Plana","state":"Castellon","zip":"12002","country":"Spain"},{"facility":"Hospital Universitario A Coruña","city":"A Coruña","state":"LA Coruña","zip":"15006","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Hospital Universitario Cruces","city":"Barakaldo","state":"Vizcaya","zip":"48903","country":"Spain","geoPoint":{"lat":43.29639,"lon":-2.98813}},{"facility":"Hospital del Mar","city":"Barcelona","zip":"08003","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitario Vall d'Hebron - PPDS","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Complejo Hospitalario de Jaen","city":"Jaén","zip":"23007","country":"Spain","geoPoint":{"lat":37.76922,"lon":-3.79028}},{"facility":"Hospital Clinico San Carlos; Servicio de Oncologia","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario Virgen Macarena","city":"Seville","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Clinico Universitario de Valencia","city":"Valencia","zip":"46010","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Hospital Universitari i Politecnic La Fe de Valencia","city":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Hosp Clinico Univ Lozano Blesa; División De Oncología Médica","city":"Zaragoza","zip":"50009","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}},{"facility":"Hospital Universitario Miguel Servet","city":"Zaragoza","zip":"50009","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}},{"facility":"Prince of Songkla University; Department Of Internal Medicine, Faculty Of Medicine","city":"Hat Yai","zip":"90110","country":"Thailand","geoPoint":{"lat":7.00836,"lon":100.47668}},{"facility":"Khon Kaen University","city":"Khon Kaen","zip":"40002","country":"Thailand","geoPoint":{"lat":16.44671,"lon":102.833}},{"facility":"Chiang Rai Prachanukroh Hospital","city":"Muang","zip":"57000","country":"Thailand"},{"facility":"Buddhachinnaraj Hospital","city":"Phitsanulok","zip":"65000","country":"Thailand","geoPoint":{"lat":16.82481,"lon":100.25858}},{"facility":"Cukurova University Medical Faculty Balcali Hospital","city":"Adana","zip":"1330","country":"Turkey (Türkiye)","geoPoint":{"lat":36.98615,"lon":35.32531}},{"facility":"Hacettepe Universitesi Tip Fakultesi Hastanesi","city":"Ankara","zip":"06100","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Istanbul University Cerrahpasa Medical Faculty","city":"Istanbul","zip":"34000","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Ege Universitesi Tip Fakultesi Hastanesi","city":"Izmir","zip":"35100","country":"Turkey (Türkiye)","geoPoint":{"lat":38.41273,"lon":27.13838}},{"facility":"Izmir Dr. Suat Seren Gogus Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi","city":"Izmir","zip":"35110","country":"Turkey (Türkiye)","geoPoint":{"lat":38.41273,"lon":27.13838}},{"facility":"Inonu University Faculty of Medicine Turgut Ozal Medical Center","city":"Malatya","zip":"44280","country":"Turkey (Türkiye)","geoPoint":{"lat":38.35018,"lon":38.31667}},{"facility":"Municipal Noncommercial Institution Regional Center of Oncology","city":"Kharkiv","state":"Kharkiv Governorate","zip":"61070","country":"Ukraine","geoPoint":{"lat":49.98177,"lon":36.25475}},{"facility":"Municipal Noncomercial Enterprise Odessa Regional Oncology Center ofthe Odessa StateAdministration","city":"Odesa","state":"Kherson Governorate","zip":"65055","country":"Ukraine","geoPoint":{"lat":46.48572,"lon":30.74383}},{"facility":"Municipal non profit enterprise of Sumy Regional Council Sumy Regional Clinical Oncology Disp","city":"Sumy","state":"Kholm Governorate","zip":"40005","country":"Ukraine","geoPoint":{"lat":50.91741,"lon":34.79906}},{"facility":"Communal Non-profit Enterprise City Clinical Hospital #4 of Dnipro City Council - PPDS; Chemotherapy","city":"Dnipro","state":"KIEV Governorate","zip":"49102","country":"Ukraine","geoPoint":{"lat":48.46664,"lon":35.04066}},{"facility":"Kyiv Railway Clinical Hospital #3 of Branch Health Center of the PJSC Ukrainian Railway","city":"Kyiv","state":"KIEV Governorate","zip":"02096","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Communal Nonprofit Enterprise Podilsky Regional Center Of Oncology OfTheVinnytsia Regional Council","city":"Vinnytsia","state":"KIEV Governorate","zip":"21029","country":"Ukraine","geoPoint":{"lat":49.2322,"lon":28.46871}},{"facility":"The Municipal Enterprise Volyn Regional Medical Oncology Centre of the Volyn Regional Council","city":"Lutsk","state":"Volhynian Governorate","zip":"43018","country":"Ukraine","geoPoint":{"lat":50.75784,"lon":25.35024}},{"facility":"Private Enterprise Private Manufacturing Company Acinus","city":"Kirovograd","zip":"25006","country":"Ukraine","geoPoint":{"lat":48.50834,"lon":32.26618}},{"facility":"Birmingham Heartlands Hospital","city":"Birmingham","zip":"B9 5SS","country":"United Kingdom","geoPoint":{"lat":52.48142,"lon":-1.89983}},{"facility":"Colchester General Hospital","city":"Colchester, Essex","zip":"CO4 5JL","country":"United Kingdom","geoPoint":{"lat":51.88921,"lon":0.90421}},{"facility":"Christie Hospital","city":"Manchester","zip":"M20 3BG","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}}]},"referencesModule":{"references":[{"pmid":"39532375","type":"DERIVED","citation":"Li B, Rong D, Lin H. Atezolizumab monotherapy as first-line treatment for non-small cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a cost-effectiveness analysis in the USA. BMJ Open. 2024 Nov 12;14(11):e083716. doi: 10.1136/bmjopen-2023-083716."},{"pmid":"32997907","type":"DERIVED","citation":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, Ozguroglu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, McCleland M, Mocci S, Jassem J, Spigel DR. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020 Oct 1;383(14):1328-1339. doi: 10.1056/NEJMoa1917346."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Study is considered 'Completed' because all of the criteria for End of Study have been met. Participants in survival follow-up completed their last visit and participants on active treatment were rolled over to a rollover study to continue their treatment.","recruitmentDetails":"Recruitment included: Japan (16 centers), Spain (15 centers), Greece (12 centers), Italy (12 centers), Brazil (11 centers), Russian (11 centers), France (10 centers), United States of America (9 centers), Ukraine (8 centers), Romania (7 centers), Turkey (6 centers), Poland (5 centers), Serbia (5 centers), Hungary (4 centers), Thailand (4 centers), Great Britain (3 centers), Republic of Korea (3 centers), Germany (2 centers), China (1 center).","groups":[{"id":"FG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"FG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"287"},{"groupId":"FG001","numSubjects":"285"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"287"},{"groupId":"FG001","numSubjects":"285"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"211"},{"groupId":"FG001","numSubjects":"201"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"17"}]},{"type":"Study Terminated By Sponsor","reasons":[{"groupId":"FG000","numSubjects":"48"},{"groupId":"FG001","numSubjects":"59"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Local ethics requires subjects' data be removed from aug 2020 to currently.","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Participant Moved Into Roll-Over Study","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"BG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"287"},{"groupId":"BG001","value":"285"},{"groupId":"BG002","value":"572"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.8","spread":"8.8"},{"groupId":"BG001","value":"63.1","spread":"8.8"},{"groupId":"BG002","value":"63.4","spread":"8.8"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"89"},{"groupId":"BG001","value":"87"},{"groupId":"BG002","value":"176"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"198"},{"groupId":"BG001","value":"198"},{"groupId":"BG002","value":"396"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"35"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"265"},{"groupId":"BG001","value":"262"},{"groupId":"BG002","value":"527"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"10"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"81"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"232"},{"groupId":"BG002","value":"479"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"7"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS) in the TC3 or IC3-WT Populations","description":"OS is defined as the time from randomization to death from any cause.","populationDescription":"Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \\[WT\\]).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"107"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","lowerLimit":"7.4","upperLimit":"16.5"},{"groupId":"OG001","value":"20.2","lowerLimit":"16.5","upperLimit":"NA","comment":"Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"TC3 or IC3-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified analysis. OS was tested hierarchically in the efficacy analysis populations.","pValue":"0.0106","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.595","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.398","ciUpperLimit":"0.890"}]},{"type":"PRIMARY","title":"Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations","description":"OS is defined as the time from randomization to death from any cause.","populationDescription":"Analysis was performed for the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \\[WT\\]).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From randomization to death from any cause until data cut-off on 4 February 2020 (up to approximately 54.5 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"277"}]}],"classes":[{"title":"TC2/3 or IC2/3-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","lowerLimit":"12.6","upperLimit":"18.0"},{"groupId":"OG001","value":"19.9","lowerLimit":"17.2","upperLimit":"25.3"}]}]},{"title":"TC1/2/3 or IC1/2/3-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"277"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","lowerLimit":"11.2","upperLimit":"16.5"},{"groupId":"OG001","value":"18.9","lowerLimit":"13.4","upperLimit":"23.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"TC2/3 or IC2/3-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified analysis. OS was tested hierarchically in the efficacy analysis populations.","pValue":"0.3091","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.868","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.661","ciUpperLimit":"1.140"},{"groupIds":["OG000","OG001"],"groupDescription":"TC1/2/3 or IC/1/2/3-WT","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified analysis. OS was tested hierarchically in the efficacy analysis populations.","pValue":"0.1070","pValueComment":"P-value is descriptive as it was not formally tested.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.845","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.688","ciUpperLimit":"1.037"}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS) in the TC3 or IC3-WT Populations","description":"PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first. PFS could not be formally tested.","populationDescription":"Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \\[WT\\]).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"107"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","lowerLimit":"4.2","upperLimit":"5.7"},{"groupId":"OG001","value":"8.1","lowerLimit":"6.8","upperLimit":"11.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"TC3 or IC3-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.0070","pValueComment":"P-value is descriptive as it was not formally tested.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.630","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.449","ciUpperLimit":"0.884"}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations","description":"PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first. PFS could not be formally tested.","populationDescription":"Analysis was performed for the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \\[WT\\]).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 4 February 2020 (up to approximately 54.5 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"277"}]}],"classes":[{"title":"TC2/3 or IC2/3-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","lowerLimit":"4.5","upperLimit":"5.7"},{"groupId":"OG001","value":"7.3","lowerLimit":"5.6","upperLimit":"9.3"}]}]},{"title":"TC1/2/3 or IC1/2/3-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"277"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"4.7","upperLimit":"5.7"},{"groupId":"OG001","value":"5.8","lowerLimit":"5.5","upperLimit":"7.3"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"TC2/3 or IC2/3-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.0004","pValueComment":"P-value is descriptive as it was not formally tested.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.641","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.501","ciUpperLimit":"0.820"},{"groupIds":["OG000","OG001"],"groupDescription":"TC1/2/3 or IC1/2/3-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","pValue":"0.0004","pValueComment":"P-value is descriptive as it was not formally tested.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.716","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.595","ciUpperLimit":"0.863"}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response (ORR) in the TC3 or IC3-WT Populations","description":"Objective response (partial response plus complete response) as determined by the investigator according to RECIST v1.1.","populationDescription":"Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \\[WT\\]).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Every 6 weeks for 48 weeks following Day 1, thereafter every 9 weeks after completion of Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression until data cut-off on 10 Sep 2018 (up to approximately 38 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"107"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6"},{"groupId":"OG001","value":"38.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"TC3 or IC3-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","paramType":"Difference in ORR","paramValue":"9.75","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.07","ciUpperLimit":"23.56"}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response (ORR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations","description":"Objective response (partial response plus complete response) as determined by the investigator according to RECIST v1.1.","populationDescription":"Analysis was performed for the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \\[WT\\]).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Every 6 weeks for 48 weeks following Day 1, thereafter every 9 weeks after completion of Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression until data cut-off on 4 Feb 2020 (up to approximately 54.5 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"277"}]}],"classes":[{"title":"TC2/3 or IC2/3-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.1"},{"groupId":"OG001","value":"33.7"}]}]},{"title":"TC1/2/3 or IC1/2/3-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"277"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.1"},{"groupId":"OG001","value":"31.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"TC2/3 or IC2/3-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified analysis","paramType":"Difference in ORR","paramValue":"1.64","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.14","ciUpperLimit":"12.42"},{"groupIds":["OG000","OG001"],"groupDescription":"TC1/2/3 or IC1/2/3-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified analysis","paramType":"Difference in ORR","paramValue":"-0.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.84","ciUpperLimit":"7.39"}]},{"type":"SECONDARY","title":"Duration of Response (DOR) in the TC3 or IC3-WT Populations","description":"DOR is defined as the time from the first occurrence of a documented objective response to the time of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first.","populationDescription":"Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \\[WT\\]).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From first occurrence of a complete response or partial response, whichever occurs first, until first date that progressive disease or death is documented, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"41"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"5.5","upperLimit":"17.3"},{"groupId":"OG001","value":"NA","lowerLimit":"11.8","upperLimit":"NA","comment":"Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"TC3 or IC3-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.365","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.166","ciUpperLimit":"0.800"}]},{"type":"SECONDARY","title":"Duration of Response (DOR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations","description":"DOR is defined as the time from the first occurrence of a documented objective response to the time of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first.","populationDescription":"Analysis was performed for the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \\[WT\\]).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From first occurrence of a complete response or partial response, whichever occurs first, until first date that progressive disease or death is documented, whichever occurs first until data cut-off on 4 February 2020 (up to approximately 54.5 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"87"}]}],"classes":[{"title":"TC2/3 or IC2/3-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"56"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","lowerLimit":"5.1","upperLimit":"9.8"},{"groupId":"OG001","value":"38.9","lowerLimit":"16.9","upperLimit":"NA","comment":"Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events."}]}]},{"title":"TC1/2/3 or IC1/2/3-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"87"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","lowerLimit":"5.1","upperLimit":"8.8"},{"groupId":"OG001","value":"26.3","lowerLimit":"16.1","upperLimit":"43.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"TC2/3 or IC2/3-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.235","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.135","ciUpperLimit":"0.409"},{"groupIds":["OG000","OG001"],"groupDescription":"TC1/2/3 or IC1/2/3-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.284","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.190","ciUpperLimit":"0.424"}]},{"type":"SECONDARY","title":"Percentage of Participants Who Are Alive at 1 Year in the TC3 or IC3-WT Populations","populationDescription":"Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \\[WT\\]).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline to 1 year or death, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"107"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.64","lowerLimit":"40.00","upperLimit":"61.27"},{"groupId":"OG001","value":"64.90","lowerLimit":"55.36","upperLimit":"74.43"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"1-Year TC3 or IC3-WT Population","nonInferiorityType":"SUPERIORITY","paramType":"Difference in Event Free Rate","paramValue":"14.26","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.03","ciUpperLimit":"28.55"}]},{"type":"SECONDARY","title":"Percentage of Participants Who Are Alive at 2 Years in the TC3 or IC3-WT Populations","populationDescription":"Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \\[WT\\]).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline to 2 years or death, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"107"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.79","lowerLimit":"13.11","upperLimit":"36.47"},{"groupId":"OG001","value":"45.49","lowerLimit":"32.11","upperLimit":"58.88"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"2-Years TC3 or IC3-WT Population","nonInferiorityType":"SUPERIORITY","paramType":"Difference in Event Free Rate","paramValue":"20.70","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.94","ciUpperLimit":"38.47"}]},{"type":"SECONDARY","title":"Percentage of Participants Who Are Alive at 1 Year in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations","populationDescription":"Analysis was performed for the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \\[WT\\]).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline to 1 year or death, whichever occurs first until clinical cut-off date on 4 February 2020 (up to approximately 54.5 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months). Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"277"}]}],"classes":[{"title":"1-Year TC2/3 or IC2/3-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.65","lowerLimit":"50.95","upperLimit":"66.35"},{"groupId":"OG001","value":"63.39","lowerLimit":"56.00","upperLimit":"70.77"}]}]},{"title":"1-Year TC1/2/3 or IC1/2/3-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"277"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54.89","lowerLimit":"48.93","upperLimit":"60.84"},{"groupId":"OG001","value":"59.95","lowerLimit":"54.12","upperLimit":"65.78"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"1-Year TC2/3 or IC2/3-WT Population","nonInferiorityType":"SUPERIORITY","paramType":"Difference in Event Free Rate","paramValue":"4.74","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.93","ciUpperLimit":"15.40"},{"groupIds":["OG000","OG001"],"groupDescription":"1-Year TC1/2/3 or IC1/2/3-WT Population","nonInferiorityType":"SUPERIORITY","paramType":"Difference in Event Free Rate","paramValue":"5.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.27","ciUpperLimit":"13.40"}]},{"type":"SECONDARY","title":"Percentage of Participants Who Are Alive at 2 Years in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations","populationDescription":"Analysis was performed for the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \\[WT\\]).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline to 2 years or death, whichever occurs first until clinical cut-off date on 4 February 2020 (up to approximately 54.5 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months). Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"277"}]}],"classes":[{"title":"2-Years TC2/3 or IC2/3-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.42","lowerLimit":"27.91","upperLimit":"42.94"},{"groupId":"OG001","value":"44.15","lowerLimit":"36.51","upperLimit":"51.80"}]}]},{"title":"2-Years TC1/2/3 or IC1/2/3-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"277"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.82","lowerLimit":"25.28","upperLimit":"36.36"},{"groupId":"OG001","value":"41.76","lowerLimit":"35.84","upperLimit":"47.67"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"2-Years TC2/3 or IC2/3-WT Population","nonInferiorityType":"SUPERIORITY","paramType":"Difference in Event Free Rate","paramValue":"8.73","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.99","ciUpperLimit":"19.45"},{"groupIds":["OG000","OG001"],"groupDescription":"2-Years TC1/2/3 or IC1/2/3-WT Population","nonInferiorityType":"SUPERIORITY","paramType":"Difference in Event Free Rate","paramValue":"10.94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.83","ciUpperLimit":"19.04"}]},{"type":"SECONDARY","title":"Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Score as Assessed by the Symptoms in Lung Cancer (SILC) Scale Symptom Score in the TC3 or IC3-WT Populations","description":"TTD in each of the patient-reported lung cancer symptoms with use of the SILC scale. The SILC scale is a nine-item content valid self-report measure of lung cancer symptoms. It measures severity of cough, dyspnea, and chest pain with a total symptom severity score. Each SILC symptom scale (dyspnea, cough, chest pain) score was calculated as the average of the component items (range 0 to 4). An increase in score suggested worsening in symptomatology. A symptom score change of 0.3 points for the dyspnea and cough scores was considered to be clinically significant; whereas a symptom score change of 0.5 points for the chest pain score was considered to be clinically significant.","populationDescription":"Analysis was performed for the TC3 or IC3-WT Populations.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"107"}]}],"classes":[{"title":"Cough","categories":[{"measurements":[{"groupId":"OG000","value":"3.4","lowerLimit":"1.3","upperLimit":"12.4"},{"groupId":"OG001","value":"3.5","lowerLimit":"1.0","upperLimit":"10.8"}]}]},{"title":"Dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.5","upperLimit":"1.9"},{"groupId":"OG001","value":"1.3","lowerLimit":"0.7","upperLimit":"3.6"}]}]},{"title":"Chest pain","categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.7","upperLimit":"NA","comment":"Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events."},{"groupId":"OG001","value":"1.7","lowerLimit":"0.7","upperLimit":"4.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Cough in TC3 or IC3-WT Populations","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified Analysis","paramType":"Hazard Ratio (HR)","paramValue":"1.142","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.657","ciUpperLimit":"1.984"},{"groupIds":["OG000","OG001"],"groupDescription":"Dyspnoea in TC3 or IC3-WT Populations","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.891","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.555","ciUpperLimit":"1.430"},{"groupIds":["OG000","OG001"],"groupDescription":"Chest pain in TC3 or IC3-WT Populations","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"1.229","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.737","ciUpperLimit":"2.049"}]},{"type":"SECONDARY","title":"Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations","description":"Change from baseline in each of the patient-reported lung cancer symptoms with use of the SILC scale. The SILC scale is a nine-item content valid self-report measure of lung cancer symptoms. It measures severity of cough, dyspnea, and chest pain with a total symptom severity score. Each SILC symptom scale (dyspnea, cough, chest pain) score was calculated as the average of the component items (range 0 to 4). An increase in score suggested worsening in symptomatology. A symptom score change of 0.3 points for the dyspnea and cough scores was considered to be clinically significant; whereas a symptom score change of 0.5 points for the chest pain score was considered to be clinically significant.","populationDescription":"Analysis was performed for the TC3 or IC3-WT Populations.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"61"}]}],"classes":[{"title":"Chest Pain, Week 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.57","spread":"1.23"},{"groupId":"OG001","value":"0.31","spread":"0.84"}]}]},{"title":"Chest Pain, Week 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":"1.13"},{"groupId":"OG001","value":"0.33","spread":"0.85"}]}]},{"title":"Chest Pain, Week 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"1.26"},{"groupId":"OG001","value":"0.43","spread":"0.97"}]}]},{"title":"Chest Pain, Week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"1.21"},{"groupId":"OG001","value":"0.43","spread":"1.08"}]}]},{"title":"Chest Pain, Week 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"1.19"},{"groupId":"OG001","value":"0.28","spread":"1.00"}]}]},{"title":"Chest Pain, Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"1.26"},{"groupId":"OG001","value":"0.25","spread":"0.85"}]}]},{"title":"Chest Pain, Week 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"1.04"},{"groupId":"OG001","value":"0.30","spread":"0.97"}]}]},{"title":"Chest Pain, Week 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"1.12"},{"groupId":"OG001","value":"0.20","spread":"0.82"}]}]},{"title":"Chest Pain, Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"1.00"},{"groupId":"OG001","value":"0.33","spread":"1.07"}]}]},{"title":"Chest Pain, Week 10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"1.13"},{"groupId":"OG001","value":"0.25","spread":"1.12"}]}]},{"title":"Chest Pain, Week 11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":"1.32"},{"groupId":"OG001","value":"0.21","spread":"0.96"}]}]},{"title":"Chest Pain, Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"1.33"},{"groupId":"OG001","value":"0.33","spread":"0.97"}]}]},{"title":"Chest Pain, Week 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"1.17"},{"groupId":"OG001","value":"0.30","spread":"1.04"}]}]},{"title":"Chest Pain, Week 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"1.16"},{"groupId":"OG001","value":"0.27","spread":"0.85"}]}]},{"title":"Chest Pain, Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"1.23"},{"groupId":"OG001","value":"0.45","spread":"1.01"}]}]},{"title":"Chest Pain, Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.20"},{"groupId":"OG001","value":"0.19","spread":"0.99"}]}]},{"title":"Chest Pain, Week 17","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"1.41"},{"groupId":"OG001","value":"0.22","spread":"1.20"}]}]},{"title":"Chest Pain, Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"1.26"},{"groupId":"OG001","value":"0.26","spread":"0.85"}]}]},{"title":"Chest Pain, Week 19","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"1.01"},{"groupId":"OG001","value":"0.23","spread":"0.94"}]}]},{"title":"Chest Pain, Week 20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"1.32"},{"groupId":"OG001","value":"0.23","spread":"0.95"}]}]},{"title":"Chest Pain, Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.83"},{"groupId":"OG001","value":"0.11","spread":"0.87"}]}]},{"title":"Chest Pain, Week 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"1.35"},{"groupId":"OG001","value":"0.19","spread":"1.02"}]}]},{"title":"Chest Pain, Week 23","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.00"},{"groupId":"OG001","value":"0.33","spread":"0.84"}]}]},{"title":"Chest Pain, Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.88"},{"groupId":"OG001","value":"0.18","spread":"1.13"}]}]},{"title":"Chest Pain, Week 25","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"0.79"},{"groupId":"OG001","value":"0.29","spread":"0.87"}]}]},{"title":"Chest Pain, Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"1.31"},{"groupId":"OG001","value":"0.11","spread":"0.72"}]}]},{"title":"Chest Pain, Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"1.15"},{"groupId":"OG001","value":"0.20","spread":"0.80"}]}]},{"title":"Chest Pain, Week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.81"},{"groupId":"OG001","value":"0.23","spread":"0.98"}]}]},{"title":"Chest Pain, Week 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"0.87"},{"groupId":"OG001","value":"0.18","spread":"0.80"}]}]},{"title":"Chest Pain, Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"1.45"},{"groupId":"OG001","value":"0.32","spread":"0.95"}]}]},{"title":"Chest Pain, Week 31","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"1.72"},{"groupId":"OG001","value":"0.33","spread":"0.90"}]}]},{"title":"Chest Pain, Week 32","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.41","spread":"1.61"},{"groupId":"OG001","value":"0.35","spread":"1.20"}]}]},{"title":"Chest Pain, Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.44"},{"groupId":"OG001","value":"0.04","spread":"1.03"}]}]},{"title":"Chest Pain, Week 34","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"1.31"},{"groupId":"OG001","value":"0.31","spread":"0.98"}]}]},{"title":"Chest Pain, Week 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.16"},{"groupId":"OG001","value":"0.28","spread":"1.13"}]}]},{"title":"Chest Pain, Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.85"},{"groupId":"OG001","value":"0.08","spread":"0.95"}]}]},{"title":"Chest Pain, Week 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"1.25"},{"groupId":"OG001","value":"0.39","spread":"0.89"}]}]},{"title":"Chest Pain, Week 38","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"0.72"},{"groupId":"OG001","value":"0.31","spread":"1.20"}]}]},{"title":"Chest Pain, Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"1.00"},{"groupId":"OG001","value":"0.14","spread":"0.92"}]}]},{"title":"Chest Pain, Week 40","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"1.02"},{"groupId":"OG001","value":"0.30","spread":"1.21"}]}]},{"title":"Chest Pain, Week 41","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"1.07"},{"groupId":"OG001","value":"0.30","spread":"1.01"}]}]},{"title":"Chest Pain, Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"1.04"},{"groupId":"OG001","value":"0.33","spread":"1.05"}]}]},{"title":"Chest Pain, Week 43","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"1.15"},{"groupId":"OG001","value":"0.18","spread":"1.29"}]}]},{"title":"Chest Pain, Week 44","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"0.99"},{"groupId":"OG001","value":"0.42","spread":"1.15"}]}]},{"title":"Chest Pain, Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"0.48"},{"groupId":"OG001","value":"0.31","spread":"0.90"}]}]},{"title":"Chest Pain, Week 46","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.45"},{"groupId":"OG001","value":"0.37","spread":"0.93"}]}]},{"title":"Chest Pain, Week 47","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.71"},{"groupId":"OG001","value":"0.31","spread":"0.86"}]}]},{"title":"Chest Pain, Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.50"},{"groupId":"OG001","value":"0.17","spread":"0.79"}]}]},{"title":"Chest Pain, Week 49","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"1.32"},{"groupId":"OG001","value":"0.47","spread":"1.07"}]}]},{"title":"Chest Pain, Week 50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"0.91"},{"groupId":"OG001","value":"0.20","spread":"0.92"}]}]},{"title":"Chest Pain, Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.88","spread":"0.85"},{"groupId":"OG001","value":"0.31","spread":"0.89"}]}]},{"title":"Chest Pain, Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"1.19"},{"groupId":"OG001","value":"0.54","spread":"1.11"}]}]},{"title":"Chest Pain, Week 53","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"0.84"},{"groupId":"OG001","value":"0.29","spread":"1.08"}]}]},{"title":"Chest Pain, Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":"1.03"},{"groupId":"OG001","value":"0.25","spread":"0.87"}]}]},{"title":"Chest Pain, Week 55","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"1.26"},{"groupId":"OG001","value":"0.15","spread":"0.99"}]}]},{"title":"Chest Pain, Week 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":"0.48"},{"groupId":"OG001","value":"0.29","spread":"0.96"}]}]},{"title":"Chest Pain, Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.58"},{"groupId":"OG001","value":"0.08","spread":"0.73"}]}]},{"title":"Chest Pain, Week 58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"1.04"},{"groupId":"OG001","value":"0.19","spread":"1.07"}]}]},{"title":"Chest Pain, Week 59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.87"},{"groupId":"OG001","value":"0.00","spread":"0.87"}]}]},{"title":"Chest Pain, Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"1.41"},{"groupId":"OG001","value":"0.38","spread":"1.08"}]}]},{"title":"Chest Pain, Week 61","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.87"},{"groupId":"OG001","value":"0.36","spread":"1.12"}]}]},{"title":"Chest Pain, Week 62","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.76"},{"groupId":"OG001","value":"0.43","spread":"1.16"}]}]},{"title":"Chest Pain, Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.71"},{"groupId":"OG001","value":"0.29","spread":"0.86"}]}]},{"title":"Chest Pain, Week 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.40","spread":"1.22"}]}]},{"title":"Chest Pain, Week 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.35","spread":"1.11"}]}]},{"title":"Chest Pain, Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.45","spread":"1.44"}]}]},{"title":"Chest Pain, Week 67","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"1.41"},{"groupId":"OG001","value":"-0.09","spread":"0.80"}]}]},{"title":"Chest Pain, Week 68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"1.06"},{"groupId":"OG001","value":"0.39","spread":"1.45"}]}]},{"title":"Chest Pain, Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.71"},{"groupId":"OG001","value":"0.50","spread":"1.33"}]}]},{"title":"Chest Pain, Week 70","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"1.41"},{"groupId":"OG001","value":"0.18","spread":"0.81"}]}]},{"title":"Chest Pain, Week 71","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.71"},{"groupId":"OG001","value":"0.45","spread":"1.32"}]}]},{"title":"Chest Pain, Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00"},{"groupId":"OG001","value":"0.42","spread":"1.18"}]}]},{"title":"Chest Pain, Week 73","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.50"},{"groupId":"OG001","value":"0.27","spread":"1.19"}]}]},{"title":"Chest Pain, Week 74","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.71"},{"groupId":"OG001","value":"0.50","spread":"1.30"}]}]},{"title":"Chest Pain, Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"1.06"},{"groupId":"OG001","value":"0.33","spread":"1.32"}]}]},{"title":"Chest Pain, Week 76","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.71"},{"groupId":"OG001","value":"0.00","spread":"0.93"}]}]},{"title":"Chest Pain, Week 77","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.71"},{"groupId":"OG001","value":"0.19","spread":"1.33"}]}]},{"title":"Chest Pain, Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"1.41"},{"groupId":"OG001","value":"0.21","spread":"1.44"}]}]},{"title":"Chest Pain, Week 79","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.71"},{"groupId":"OG001","value":"0.31","spread":"1.31"}]}]},{"title":"Chest Pain, Week 80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"1.06"},{"groupId":"OG001","value":"0.72","spread":"1.70"}]}]},{"title":"Chest Pain, Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"1.06"},{"groupId":"OG001","value":"0.08","spread":"1.72"}]}]},{"title":"Chest Pain, Week 82","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.08","spread":"1.24"}]}]},{"title":"Chest Pain, Week 83","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.50","spread":"1.48"}]}]},{"title":"Chest Pain, Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50"},{"groupId":"OG001","value":"0.43","spread":"1.43"}]}]},{"title":"Chest Pain, Week 85","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.38","spread":"1.41"}]}]},{"title":"Chest Pain, Week 86","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.21","spread":"1.44"}]}]},{"title":"Chest Pain, Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.29","spread":"1.41"}]}]},{"title":"Chest Pain, Week 88","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.43","spread":"1.17"}]}]},{"title":"Chest Pain, Week 89","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-0.20","spread":"0.91"}]}]},{"title":"Chest Pain, Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.07","spread":"1.13"}]}]},{"title":"Chest Pain, Week 91","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-0.07","spread":"0.89"}]}]},{"title":"Chest Pain, Week 92","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.33","spread":"1.54"}]}]},{"title":"Chest Pain, Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"1.47"}]}]},{"title":"Chest Pain, Week 94","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.20","spread":"1.35"}]}]},{"title":"Chest Pain, Week 95","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.33","spread":"1.54"}]}]},{"title":"Chest Pain, Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.33","spread":"1.54"}]}]},{"title":"Chest Pain, Week 97","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"1.47"}]}]},{"title":"Chest Pain, Week 98","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.33","spread":"1.54"}]}]},{"title":"Chest Pain, Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.88","spread":"1.18"}]}]},{"title":"Chest Pain, Week 100","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"1.00"}]}]},{"title":"Chest Pain, Week 101","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.83","spread":"0.93"}]}]},{"title":"Chest Pain, Week 102","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"1.00"}]}]},{"title":"Chest Pain, Week 103","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.63","spread":"1.11"}]}]},{"title":"Chest Pain, Week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.00","spread":"1.00"}]}]},{"title":"Chest Pain, Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.00","spread":"1.00"}]}]},{"title":"Chest Pain, Week 106","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"0.71"}]}]},{"title":"Chest Pain, Week 107","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.00","spread":"1.00"}]}]},{"title":"Chest Pain, Week 108","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.50","spread":"0.71"}]}]},{"title":"Chest Pain, Week 109","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.75","spread":"1.06"}]}]},{"title":"Chest Pain, Week 110","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00","spread":"1.41"}]}]},{"title":"Chest Pain, Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.50","spread":"0.71"}]}]},{"title":"Chest Pain, Week 112","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.50","spread":"0.71"}]}]},{"title":"Chest Pain, Week 113","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.50","spread":"0.71"}]}]},{"title":"Chest Pain, Week 114","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00","spread":"1.41"}]}]},{"title":"Chest Pain, Week 115","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.75","spread":"1.06"}]}]},{"title":"Chest Pain, Week 116","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00","spread":"1.41"}]}]},{"title":"Chest Pain, Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00","spread":"1.41"}]}]},{"title":"Chest Pain, Week 118","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00","spread":"1.41"}]}]},{"title":"Chest Pain, Week 119","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.75","spread":"1.06"}]}]},{"title":"Chest Pain, Week 120","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.50"}]}]},{"title":"Chest Pain, Week 121","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00"}]}]},{"title":"Chest Pain, Week 122","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"3.00"}]}]},{"title":"Chest Pain, Week 123","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.50"}]}]},{"title":"Chest Pain, Week 124","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"3.00"}]}]},{"title":"Chest Pain, Week 125","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"3.00"}]}]},{"title":"Chest Pain, Week 126","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"3.00"}]}]},{"title":"Chest Pain, Week 127","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00"}]}]},{"title":"Chest Pain, Week 128","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"3.00"}]}]},{"title":"Chest Pain, Week 129","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"3.00"}]}]},{"title":"Chest Pain, Week 130","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00"}]}]},{"title":"Chest Pain, Week 131","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00"}]}]},{"title":"Cough, Week 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.86"},{"groupId":"OG001","value":"0.10","spread":"0.70"}]}]},{"title":"Cough, Week 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.99"},{"groupId":"OG001","value":"0.19","spread":"0.75"}]}]},{"title":"Cough, Week 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.76"},{"groupId":"OG001","value":"-0.01","spread":"0.76"}]}]},{"title":"Cough, Week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"1.02"},{"groupId":"OG001","value":"-0.03","spread":"0.98"}]}]},{"title":"Cough, Week 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.84"},{"groupId":"OG001","value":"0.00","spread":"0.96"}]}]},{"title":"Cough, Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"0.93"},{"groupId":"OG001","value":"-0.18","spread":"0.89"}]}]},{"title":"Cough, Week 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"0.92"},{"groupId":"OG001","value":"-0.06","spread":"0.98"}]}]},{"title":"Cough, Week 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"0.90"},{"groupId":"OG001","value":"-0.13","spread":"0.91"}]}]},{"title":"Cough, Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"0.86"},{"groupId":"OG001","value":"-0.06","spread":"1.01"}]}]},{"title":"Cough, Week 10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"1.12"},{"groupId":"OG001","value":"-0.10","spread":"1.02"}]}]},{"title":"Cough, Week 11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"1.24"},{"groupId":"OG001","value":"-0.07","spread":"1.07"}]}]},{"title":"Cough, Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"1.30"},{"groupId":"OG001","value":"-0.09","spread":"0.97"}]}]},{"title":"Cough, Week 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"1.22"},{"groupId":"OG001","value":"-0.20","spread":"0.93"}]}]},{"title":"Cough, Week 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"1.19"},{"groupId":"OG001","value":"-0.07","spread":"0.95"}]}]},{"title":"Cough, Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"1.35"},{"groupId":"OG001","value":"-0.19","spread":"1.04"}]}]},{"title":"Cough, Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"1.06"},{"groupId":"OG001","value":"-0.19","spread":"0.94"}]}]},{"title":"Cough, Week 17","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.99"},{"groupId":"OG001","value":"-0.21","spread":"1.09"}]}]},{"title":"Cough, Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"1.23"},{"groupId":"OG001","value":"-0.26","spread":"0.93"}]}]},{"title":"Cough, Week 19","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.23","spread":"1.29"},{"groupId":"OG001","value":"-0.27","spread":"0.87"}]}]},{"title":"Cough, Week 20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.33"},{"groupId":"OG001","value":"-0.33","spread":"0.95"}]}]},{"title":"Cough, Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"1.40"},{"groupId":"OG001","value":"-0.19","spread":"0.88"}]}]},{"title":"Cough, Week 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"1.32"},{"groupId":"OG001","value":"-0.17","spread":"0.89"}]}]},{"title":"Cough, Week 23","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":"1.18"},{"groupId":"OG001","value":"0.05","spread":"0.90"}]}]},{"title":"Cough, Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"1.51"},{"groupId":"OG001","value":"-0.12","spread":"0.80"}]}]},{"title":"Cough, Week 25","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.45","spread":"0.96"},{"groupId":"OG001","value":"0.14","spread":"0.82"}]}]},{"title":"Cough, Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":"1.20"},{"groupId":"OG001","value":"-0.03","spread":"0.89"}]}]},{"title":"Cough, Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"1.22"},{"groupId":"OG001","value":"-0.05","spread":"0.94"}]}]},{"title":"Cough, Week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.45","spread":"0.88"},{"groupId":"OG001","value":"0.08","spread":"0.84"}]}]},{"title":"Cough, Week 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"1.31"},{"groupId":"OG001","value":"0.05","spread":"0.67"}]}]},{"title":"Cough, Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.88","spread":"1.13"},{"groupId":"OG001","value":"0.12","spread":"0.88"}]}]},{"title":"Cough, Week 31","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.86","spread":"1.40"},{"groupId":"OG001","value":"0.05","spread":"0.74"}]}]},{"title":"Cough, Week 32","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.73","spread":"1.56"},{"groupId":"OG001","value":"-0.04","spread":"1.04"}]}]},{"title":"Cough, Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.77","spread":"1.13"},{"groupId":"OG001","value":"-0.29","spread":"1.06"}]}]},{"title":"Cough, Week 34","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.80","spread":"1.18"},{"groupId":"OG001","value":"-0.02","spread":"0.75"}]}]},{"title":"Cough, Week 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.95"},{"groupId":"OG001","value":"-0.09","spread":"1.10"}]}]},{"title":"Cough, Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"0.66"},{"groupId":"OG001","value":"-0.36","spread":"1.16"}]}]},{"title":"Cough, Week 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"0.89"},{"groupId":"OG001","value":"-0.04","spread":"0.84"}]}]},{"title":"Cough, Week 38","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.88"},{"groupId":"OG001","value":"-0.07","spread":"1.11"}]}]},{"title":"Cough, Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"0.90"},{"groupId":"OG001","value":"-0.20","spread":"0.97"}]}]},{"title":"Cough, Week 40","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.36","spread":"0.94"},{"groupId":"OG001","value":"-0.39","spread":"1.23"}]}]},{"title":"Cough, Week 41","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"0.57"},{"groupId":"OG001","value":"0.05","spread":"0.84"}]}]},{"title":"Cough, Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"0.52"},{"groupId":"OG001","value":"-0.20","spread":"1.16"}]}]},{"title":"Cough, Week 43","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.55"},{"groupId":"OG001","value":"0.03","spread":"1.06"}]}]},{"title":"Cough, Week 44","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"0.94"},{"groupId":"OG001","value":"-0.11","spread":"1.09"}]}]},{"title":"Cough, Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.50"},{"groupId":"OG001","value":"-0.26","spread":"0.92"}]}]},{"title":"Cough, Week 46","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.96"},{"groupId":"OG001","value":"0.08","spread":"0.85"}]}]},{"title":"Cough, Week 47","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.58"},{"groupId":"OG001","value":"-0.03","spread":"0.90"}]}]},{"title":"Cough, Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"0.29"},{"groupId":"OG001","value":"0.23","spread":"0.68"}]}]},{"title":"Cough, Week 49","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.76"},{"groupId":"OG001","value":"0.26","spread":"0.85"}]}]},{"title":"Cough, Week 50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.76"},{"groupId":"OG001","value":"0.00","spread":"0.85"}]}]},{"title":"Cough, Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.63"},{"groupId":"OG001","value":"0.06","spread":"0.93"}]}]},{"title":"Cough, Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"0.95"},{"groupId":"OG001","value":"0.27","spread":"0.97"}]}]},{"title":"Cough, Week 53","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"0.76"},{"groupId":"OG001","value":"0.38","spread":"0.71"}]}]},{"title":"Cough, Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.41"},{"groupId":"OG001","value":"0.07","spread":"0.70"}]}]},{"title":"Cough, Week 55","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.29"},{"groupId":"OG001","value":"0.12","spread":"0.94"}]}]},{"title":"Cough, Week 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.41"},{"groupId":"OG001","value":"0.14","spread":"0.97"}]}]},{"title":"Cough, Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.50"},{"groupId":"OG001","value":"0.15","spread":"0.66"}]}]},{"title":"Cough, Week 58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.29"},{"groupId":"OG001","value":"0.08","spread":"1.00"}]}]},{"title":"Cough, Week 59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"0.58"},{"groupId":"OG001","value":"0.06","spread":"0.63"}]}]},{"title":"Cough, Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"0.35"},{"groupId":"OG001","value":"-0.04","spread":"0.83"}]}]},{"title":"Cough, Week 61","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.50"},{"groupId":"OG001","value":"0.00","spread":"0.88"}]}]},{"title":"Cough, Week 62","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"0.58"},{"groupId":"OG001","value":"0.14","spread":"0.79"}]}]},{"title":"Cough, Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"-0.04","spread":"0.86"}]}]},{"title":"Cough, Week 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.35","spread":"1.00"}]}]},{"title":"Cough, Week 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50"},{"groupId":"OG001","value":"0.12","spread":"0.92"}]}]},{"title":"Cough, Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.45","spread":"1.21"}]}]},{"title":"Cough, Week 67","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.35"},{"groupId":"OG001","value":"-0.09","spread":"0.66"}]}]},{"title":"Cough, Week 68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.35"},{"groupId":"OG001","value":"0.61","spread":"1.29"}]}]},{"title":"Cough, Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.35"},{"groupId":"OG001","value":"0.50","spread":"1.18"}]}]},{"title":"Cough, Week 70","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.35"},{"groupId":"OG001","value":"0.23","spread":"0.79"}]}]},{"title":"Cough, Week 71","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"0.55","spread":"0.90"}]}]},{"title":"Cough, Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50"},{"groupId":"OG001","value":"0.42","spread":"0.93"}]}]},{"title":"Cough, Week 73","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.64","spread":"1.07"}]}]},{"title":"Cough, Week 74","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"0.56","spread":"1.04"}]}]},{"title":"Cough, Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.71"},{"groupId":"OG001","value":"0.67","spread":"1.35"}]}]},{"title":"Cough, Week 76","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.35"},{"groupId":"OG001","value":"0.31","spread":"1.00"}]}]},{"title":"Cough, Week 77","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"0.56","spread":"1.15"}]}]},{"title":"Cough, Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.35"},{"groupId":"OG001","value":"0.36","spread":"1.03"}]}]},{"title":"Cough, Week 79","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"0.63","spread":"1.19"}]}]},{"title":"Cough, Week 80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.35"},{"groupId":"OG001","value":"0.33","spread":"0.90"}]}]},{"title":"Cough, Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.35"},{"groupId":"OG001","value":"0.58","spread":"1.28"}]}]},{"title":"Cough, Week 82","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.25","spread":"1.08"}]}]},{"title":"Cough, Week 83","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.67","spread":"1.21"}]}]},{"title":"Cough, Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50"},{"groupId":"OG001","value":"0.29","spread":"0.95"}]}]},{"title":"Cough, Week 85","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.38","spread":"1.03"}]}]},{"title":"Cough, Week 86","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.57","spread":"1.24"}]}]},{"title":"Cough, Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.64","spread":"1.35"}]}]},{"title":"Cough, Week 88","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.64","spread":"1.14"}]}]},{"title":"Cough, Week 89","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"1.32"}]}]},{"title":"Cough, Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.43","spread":"1.10"}]}]},{"title":"Cough, Week 91","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"1.19"}]}]},{"title":"Cough, Week 92","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.67","spread":"1.21"}]}]},{"title":"Cough, Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.79","spread":"1.38"}]}]},{"title":"Cough, Week 94","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.30","spread":"0.97"}]}]},{"title":"Cough, Week 95","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.67","spread":"1.25"}]}]},{"title":"Cough, Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.58","spread":"1.20"}]}]},{"title":"Cough, Week 97","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.57","spread":"1.13"}]}]},{"title":"Cough, Week 98","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.67","spread":"1.25"}]}]},{"title":"Cough, Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.25","spread":"0.96"}]}]},{"title":"Cough, Week 100","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.60","spread":"1.14"}]}]},{"title":"Cough, Week 101","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"1.05"}]}]},{"title":"Cough, Week 102","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"1.00"}]}]},{"title":"Cough, Week 103","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.25","spread":"0.96"}]}]},{"title":"Cough, Week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.00","spread":"1.00"}]}]},{"title":"Cough, Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.33","spread":"1.53"}]}]},{"title":"Cough, Week 106","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"-0.50","spread":"0.71"}]}]},{"title":"Cough, Week 107","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.00","spread":"1.00"}]}]},{"title":"Cough, Week 108","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.00","spread":"1.41"}]}]},{"title":"Cough, Week 109","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"2.12"}]}]},{"title":"Cough, Week 110","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"2.12"}]}]},{"title":"Cough, Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"2.12"}]}]},{"title":"Cough, Week 112","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.00","spread":"1.41"}]}]},{"title":"Cough, Week 113","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"2.12"}]}]},{"title":"Cough, Week 114","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"2.12"}]}]},{"title":"Cough, Week 115","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"2.12"}]}]},{"title":"Cough, Week 116","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"2.12"}]}]},{"title":"Cough, Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"2.12"}]}]},{"title":"Cough, Week 118","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"2.12"}]}]},{"title":"Cough, Week 119","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.50","spread":"2.12"}]}]},{"title":"Cough, Week 120","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00"}]}]},{"title":"Cough, Week 121","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00"}]}]},{"title":"Cough, Week 122","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00"}]}]},{"title":"Cough, Week 123","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00"}]}]},{"title":"Cough, Week 124","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00"}]}]},{"title":"Cough, Week 125","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00"}]}]},{"title":"Cough, Week 126","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00"}]}]},{"title":"Cough, Week 127","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00"}]}]},{"title":"Cough, Week 128","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00"}]}]},{"title":"Cough, Week 129","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00"}]}]},{"title":"Cough, Week 130","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00"}]}]},{"title":"Cough, Week 131","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00"}]}]},{"title":"Dyspnoea, Week 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":"0.81"},{"groupId":"OG001","value":"0.12","spread":"0.76"}]}]},{"title":"Dyspnoea, Week 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"0.73"},{"groupId":"OG001","value":"0.29","spread":"0.87"}]}]},{"title":"Dyspnoea, Week 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.75"},{"groupId":"OG001","value":"0.25","spread":"0.97"}]}]},{"title":"Dyspnoea, Week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"0.87"},{"groupId":"OG001","value":"0.28","spread":"0.89"}]}]},{"title":"Dyspnoea, Week 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.55","spread":"0.81"},{"groupId":"OG001","value":"0.21","spread":"1.00"}]}]},{"title":"Dyspnoea, Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.68"},{"groupId":"OG001","value":"0.21","spread":"0.95"}]}]},{"title":"Dyspnoea, Week 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"0.74"},{"groupId":"OG001","value":"0.32","spread":"1.08"}]}]},{"title":"Dyspnoea, Week 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.64"},{"groupId":"OG001","value":"0.25","spread":"1.00"}]}]},{"title":"Dyspnoea, Week 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"0.86"},{"groupId":"OG001","value":"0.34","spread":"1.01"}]}]},{"title":"Dyspnoea, Week 10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"0.80"},{"groupId":"OG001","value":"0.49","spread":"1.12"}]}]},{"title":"Dyspnoea, Week 11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"0.77"},{"groupId":"OG001","value":"0.24","spread":"0.97"}]}]},{"title":"Dyspnoea, Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":"0.82"},{"groupId":"OG001","value":"0.35","spread":"1.04"}]}]},{"title":"Dyspnoea, Week 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"0.83"},{"groupId":"OG001","value":"0.23","spread":"0.94"}]}]},{"title":"Dyspnoea, Week 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":"0.88"},{"groupId":"OG001","value":"0.26","spread":"1.14"}]}]},{"title":"Dyspnoea, Week 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"1.07"},{"groupId":"OG001","value":"0.39","spread":"1.22"}]}]},{"title":"Dyspnoea, Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"0.82"},{"groupId":"OG001","value":"0.26","spread":"1.13"}]}]},{"title":"Dyspnoea, Week 17","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"0.87"},{"groupId":"OG001","value":"0.16","spread":"1.17"}]}]},{"title":"Dyspnoea, Week 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":"0.65"},{"groupId":"OG001","value":"0.21","spread":"1.05"}]}]},{"title":"Dyspnoea, Week 19","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"0.86"},{"groupId":"OG001","value":"0.33","spread":"1.12"}]}]},{"title":"Dyspnoea, Week 20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"0.87"},{"groupId":"OG001","value":"0.23","spread":"1.00"}]}]},{"title":"Dyspnoea, Week 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"0.69"},{"groupId":"OG001","value":"0.40","spread":"0.93"}]}]},{"title":"Dyspnoea, Week 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.55","spread":"0.92"},{"groupId":"OG001","value":"0.22","spread":"0.99"}]}]},{"title":"Dyspnoea, Week 23","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":"0.69"},{"groupId":"OG001","value":"0.38","spread":"0.98"}]}]},{"title":"Dyspnoea, Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"1.02"},{"groupId":"OG001","value":"0.42","spread":"1.06"}]}]},{"title":"Dyspnoea, Week 25","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"0.46"},{"groupId":"OG001","value":"0.50","spread":"1.14"}]}]},{"title":"Dyspnoea, Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":"0.82"},{"groupId":"OG001","value":"0.28","spread":"0.95"}]}]},{"title":"Dyspnoea, Week 27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"1.07"},{"groupId":"OG001","value":"0.37","spread":"1.04"}]}]},{"title":"Dyspnoea, Week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"0.92"},{"groupId":"OG001","value":"0.45","spread":"0.83"}]}]},{"title":"Dyspnoea, Week 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"0.89"},{"groupId":"OG001","value":"0.38","spread":"0.85"}]}]},{"title":"Dyspnoea, Week 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"0.96"},{"groupId":"OG001","value":"0.54","spread":"1.01"}]}]},{"title":"Dyspnoea, Week 31","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"0.84"},{"groupId":"OG001","value":"0.41","spread":"0.86"}]}]},{"title":"Dyspnoea, Week 32","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"1.00"},{"groupId":"OG001","value":"0.58","spread":"1.04"}]}]},{"title":"Dyspnoea, Week 33","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"0.78"},{"groupId":"OG001","value":"0.36","spread":"0.96"}]}]},{"title":"Dyspnoea, Week 34","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"0.79"},{"groupId":"OG001","value":"0.28","spread":"1.00"}]}]},{"title":"Dyspnoea, Week 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"0.58"},{"groupId":"OG001","value":"0.27","spread":"1.02"}]}]},{"title":"Dyspnoea, Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"0.86"},{"groupId":"OG001","value":"-0.02","spread":"1.04"}]}]},{"title":"Dyspnoea, Week 37","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":"0.63"},{"groupId":"OG001","value":"0.42","spread":"1.13"}]}]},{"title":"Dyspnoea, Week 38","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.76"},{"groupId":"OG001","value":"0.50","spread":"1.25"}]}]},{"title":"Dyspnoea, Week 39","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"0.81"},{"groupId":"OG001","value":"0.25","spread":"0.86"}]}]},{"title":"Dyspnoea, Week 40","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.57","spread":"0.76"},{"groupId":"OG001","value":"0.44","spread":"1.13"}]}]},{"title":"Dyspnoea, Week 41","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"0.58"},{"groupId":"OG001","value":"0.53","spread":"1.17"}]}]},{"title":"Dyspnoea, Week 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.55"},{"groupId":"OG001","value":"0.52","spread":"1.07"}]}]},{"title":"Dyspnoea, Week 43","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.57"},{"groupId":"OG001","value":"0.41","spread":"1.18"}]}]},{"title":"Dyspnoea, Week 44","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":"0.60"},{"groupId":"OG001","value":"0.31","spread":"1.14"}]}]},{"title":"Dyspnoea, Week 45","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"0.38"},{"groupId":"OG001","value":"0.53","spread":"1.04"}]}]},{"title":"Dyspnoea, Week 46","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":"0.71"},{"groupId":"OG001","value":"0.37","spread":"0.97"}]}]},{"title":"Dyspnoea, Week 47","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.68"},{"groupId":"OG001","value":"0.39","spread":"0.92"}]}]},{"title":"Dyspnoea, Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"0.72"},{"groupId":"OG001","value":"0.39","spread":"0.93"}]}]},{"title":"Dyspnoea, Week 49","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":"1.20"},{"groupId":"OG001","value":"0.47","spread":"0.76"}]}]},{"title":"Dyspnoea, Week 50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"0.59"},{"groupId":"OG001","value":"0.53","spread":"0.96"}]}]},{"title":"Dyspnoea, Week 51","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":"1.02"},{"groupId":"OG001","value":"0.59","spread":"1.02"}]}]},{"title":"Dyspnoea, Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":"1.01"},{"groupId":"OG001","value":"0.72","spread":"1.20"}]}]},{"title":"Dyspnoea, Week 53","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"1.28"},{"groupId":"OG001","value":"0.40","spread":"1.01"}]}]},{"title":"Dyspnoea, Week 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":"1.16"},{"groupId":"OG001","value":"0.63","spread":"1.02"}]}]},{"title":"Dyspnoea, Week 55","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.53"},{"groupId":"OG001","value":"0.72","spread":"1.13"}]}]},{"title":"Dyspnoea, Week 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.86"},{"groupId":"OG001","value":"0.61","spread":"1.07"}]}]},{"title":"Dyspnoea, Week 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":"0.61"},{"groupId":"OG001","value":"0.45","spread":"1.02"}]}]},{"title":"Dyspnoea, Week 58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"0.53"},{"groupId":"OG001","value":"0.60","spread":"1.20"}]}]},{"title":"Dyspnoea, Week 59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"0.72"},{"groupId":"OG001","value":"0.18","spread":"1.08"}]}]},{"title":"Dyspnoea, Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.20","spread":"1.13"},{"groupId":"OG001","value":"0.57","spread":"0.89"}]}]},{"title":"Dyspnoea, Week 61","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":"0.76"},{"groupId":"OG001","value":"0.54","spread":"1.00"}]}]},{"title":"Dyspnoea, Week 62","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.83"},{"groupId":"OG001","value":"0.66","spread":"1.11"}]}]},{"title":"Dyspnoea, Week 63","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.42"},{"groupId":"OG001","value":"0.77","spread":"0.80"}]}]},{"title":"Dyspnoea, Week 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.20"},{"groupId":"OG001","value":"0.66","spread":"1.07"}]}]},{"title":"Dyspnoea, Week 65","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.60"},{"groupId":"OG001","value":"0.94","spread":"1.28"}]}]},{"title":"Dyspnoea, Week 66","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40"},{"groupId":"OG001","value":"0.67","spread":"1.31"}]}]},{"title":"Dyspnoea, Week 67","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.14"},{"groupId":"OG001","value":"0.33","spread":"0.87"}]}]},{"title":"Dyspnoea, Week 68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"0.28"},{"groupId":"OG001","value":"0.82","spread":"1.56"}]}]},{"title":"Dyspnoea, Week 69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.42"},{"groupId":"OG001","value":"0.74","spread":"1.11"}]}]},{"title":"Dyspnoea, Week 70","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.42"},{"groupId":"OG001","value":"0.75","spread":"1.16"}]}]},{"title":"Dyspnoea, Week 71","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.14"},{"groupId":"OG001","value":"0.84","spread":"1.19"}]}]},{"title":"Dyspnoea, Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.80","spread":"1.09"}]}]},{"title":"Dyspnoea, Week 73","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.67","spread":"1.11"}]}]},{"title":"Dyspnoea, Week 74","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"0.28"},{"groupId":"OG001","value":"0.89","spread":"1.35"}]}]},{"title":"Dyspnoea, Week 75","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.42"},{"groupId":"OG001","value":"0.71","spread":"1.31"}]}]},{"title":"Dyspnoea, Week 76","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.42"},{"groupId":"OG001","value":"0.53","spread":"1.05"}]}]},{"title":"Dyspnoea, Week 77","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.57"},{"groupId":"OG001","value":"0.65","spread":"1.55"}]}]},{"title":"Dyspnoea, Week 78","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.14"},{"groupId":"OG001","value":"0.40","spread":"1.11"}]}]},{"title":"Dyspnoea, Week 79","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.14"},{"groupId":"OG001","value":"0.55","spread":"1.25"}]}]},{"title":"Dyspnoea, Week 80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.71"},{"groupId":"OG001","value":"0.69","spread":"1.43"}]}]},{"title":"Dyspnoea, Week 81","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.57"},{"groupId":"OG001","value":"0.53","spread":"1.53"}]}]},{"title":"Dyspnoea, Week 82","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.60"},{"groupId":"OG001","value":"0.53","spread":"1.09"}]}]},{"title":"Dyspnoea, Week 83","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.60"},{"groupId":"OG001","value":"0.87","spread":"1.28"}]}]},{"title":"Dyspnoea, Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.80"},{"groupId":"OG001","value":"0.89","spread":"1.13"}]}]},{"title":"Dyspnoea, Week 85","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.60"},{"groupId":"OG001","value":"0.83","spread":"1.27"}]}]},{"title":"Dyspnoea, Week 86","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40"},{"groupId":"OG001","value":"0.66","spread":"1.33"}]}]},{"title":"Dyspnoea, Week 87","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.40"},{"groupId":"OG001","value":"0.66","spread":"1.23"}]}]},{"title":"Dyspnoea, Week 88","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.20","spread":"1.43"}]}]},{"title":"Dyspnoea, Week 89","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.56","spread":"1.05"}]}]},{"title":"Dyspnoea, Week 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.74","spread":"1.38"}]}]},{"title":"Dyspnoea, Week 91","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.51","spread":"1.00"}]}]},{"title":"Dyspnoea, Week 92","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.87","spread":"1.26"}]}]},{"title":"Dyspnoea, Week 93","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.20","spread":"1.39"}]}]},{"title":"Dyspnoea, Week 94","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.48","spread":"0.99"}]}]},{"title":"Dyspnoea, Week 95","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.87","spread":"1.32"}]}]},{"title":"Dyspnoea, Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.13","spread":"1.24"}]}]},{"title":"Dyspnoea, Week 97","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.26","spread":"1.35"}]}]},{"title":"Dyspnoea, Week 98","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.80","spread":"1.19"}]}]},{"title":"Dyspnoea, Week 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.70","spread":"1.58"}]}]},{"title":"Dyspnoea, Week 100","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.88","spread":"1.38"}]}]},{"title":"Dyspnoea, Week 101","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.13","spread":"1.54"}]}]},{"title":"Dyspnoea, Week 102","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.96","spread":"1.58"}]}]},{"title":"Dyspnoea, Week 103","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.55","spread":"1.68"}]}]},{"title":"Dyspnoea, Week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.07","spread":"1.33"}]}]},{"title":"Dyspnoea, Week 105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.07","spread":"1.33"}]}]},{"title":"Dyspnoea, Week 106","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.40","spread":"0.28"}]}]},{"title":"Dyspnoea, Week 107","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.13","spread":"1.63"}]}]},{"title":"Dyspnoea, Week 108","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.50","spread":"1.56"}]}]},{"title":"Dyspnoea, Week 109","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.30","spread":"1.27"}]}]},{"title":"Dyspnoea, Week 110","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.50","spread":"1.56"}]}]},{"title":"Dyspnoea, Week 111","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.60","spread":"1.41"}]}]},{"title":"Dyspnoea, Week 112","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.50","spread":"1.56"}]}]},{"title":"Dyspnoea, Week 113","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.50","spread":"1.56"}]}]},{"title":"Dyspnoea, Week 114","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.60","spread":"1.70"}]}]},{"title":"Dyspnoea, Week 115","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.40","spread":"1.41"}]}]},{"title":"Dyspnoea, Week 116","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.30","spread":"1.27"}]}]},{"title":"Dyspnoea, Week 117","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.50","spread":"1.56"}]}]},{"title":"Dyspnoea, Week 118","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.30","spread":"1.27"}]}]},{"title":"Dyspnoea, Week 119","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.50","spread":"1.56"}]}]},{"title":"Dyspnoea, Week 120","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.20"}]}]},{"title":"Dyspnoea, Week 121","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.40"}]}]},{"title":"Dyspnoea, Week 122","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.20"}]}]},{"title":"Dyspnoea, Week 123","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.20"}]}]},{"title":"Dyspnoea, Week 124","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.20"}]}]},{"title":"Dyspnoea, Week 125","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.20"}]}]},{"title":"Dyspnoea, Week 126","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.20"}]}]},{"title":"Dyspnoea, Week 127","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.20"}]}]},{"title":"Dyspnoea, Week 128","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.20"}]}]},{"title":"Dyspnoea, Week 129","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.20"}]}]},{"title":"Dyspnoea, Week 130","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.20"}]}]},{"title":"Dyspnoea, Week 131","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.20"}]}]}]},{"type":"SECONDARY","title":"TTD as Assessed Using EORTC QLQ Supplementary Lung Cancer Module (EORTC QLQ-LC13) in the TC3 or IC3-WT Populations","description":"TTD in patient-reported lung cancer symptoms, defined as time from randomization to deterioration (10-point change) in any of the following symptom subscales (cough, dyspnea \\[multi-item scale\\], and chest pain), whichever occurs first, as measured by the EORTC QLQ-LC13. EORTC QLQ-LC13 module incorporates one multi-item scale to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis.","populationDescription":"Analysis was performed for the TC3 or IC3-WT Populations.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"107"}]}],"classes":[{"title":"Cough","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median TTD is not estimable by Kaplan-Meier method due to insufficient observed events.\n\nLower/Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events"},{"groupId":"OG001","value":"NA","lowerLimit":"21.5","upperLimit":"NA","comment":"Median TTD is not estimable by Kaplan-Meier method due to insufficient number of observed events.\n\nUpper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events."}]}]},{"title":"Dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"11.8","lowerLimit":"6.8","upperLimit":"19.5"},{"groupId":"OG001","value":"11.1","lowerLimit":"7.0","upperLimit":"NA","comment":"Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events."}]}]},{"title":"Chest pain","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median TTD is not estimable by Kaplan-Meier method due to insufficient number of observed events.\n\nLower/Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median TTD is not estimable by Kaplan-Meier method due to insufficient number of observed events.\n\nLower/Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Cough for TC3 or IC3-WT Populations","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.984","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.477","ciUpperLimit":"2.030"},{"groupIds":["OG000","OG001"],"groupDescription":"Dyspnea for TC3 or IC3-WT Populations","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.955","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.569","ciUpperLimit":"1.604"},{"groupIds":["OG000","OG001"],"groupDescription":"Chest pain for TC3 or IC3-WT Populations","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Stratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"1.024","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.472","ciUpperLimit":"2.222"}]},{"type":"SECONDARY","title":"OS in Participants With PD-L1 Expression","description":"OS is defined as the time from randomization to death from any cause.","populationDescription":"Analysis was performed for participants with PD-L1 Expression of PD-L1 status by SP263 \\>=50%, SP263 \\>=25%, SP263 \\>=1% in the Intent-to-Treat Wild Type Population.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"212"}]}],"classes":[{"title":"SP263 >=50%-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","lowerLimit":"9.8","upperLimit":"17.4"},{"groupId":"OG001","value":"19.5","lowerLimit":"13.8","upperLimit":"NA","comment":"Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events."}]}]},{"title":"SP263 >=25%-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"168"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","lowerLimit":"9.1","upperLimit":"17.0"},{"groupId":"OG001","value":"18.2","lowerLimit":"13.3","upperLimit":"NA","comment":"Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events."}]}]},{"title":"SP263 =1%-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"212"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","lowerLimit":"9.8","upperLimit":"16.5"},{"groupId":"OG001","value":"17.8","lowerLimit":"12.8","upperLimit":"23.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"SP263 \\>=50%-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.707","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.500","ciUpperLimit":"1.000"},{"groupIds":["OG000","OG001"],"groupDescription":"SP263 \\>=25%-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.693","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.502","ciUpperLimit":"0.956"},{"groupIds":["OG000","OG001"],"groupDescription":"SP263 \\>=1%-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.768","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.579","ciUpperLimit":"1.018"}]},{"type":"SECONDARY","title":"Investigator-Assessed PFS in Participants With PD-L1 Expression According to RECIST v1.1","description":"Investigator-assessed PFS according to RECIST v1.1 in the PD-L1 (defined with SP263 IHC assay)","populationDescription":"Analysis was performed for participants with PD-L1 Expression of PD-L1 status by SP263 \\>=50%, SP263 \\>=25%, SP263 \\>=1% in the Intent-to-Treat Wild Type Population.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"212"}]}],"classes":[{"title":"SP263 >=50%-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"150"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","lowerLimit":"4.0","upperLimit":"5.6"},{"groupId":"OG001","value":"7.0","lowerLimit":"5.6","upperLimit":"8.7"}]}]},{"title":"SP263 >=25%-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"168"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","lowerLimit":"4.2","upperLimit":"5.6"},{"groupId":"OG001","value":"6.9","lowerLimit":"5.6","upperLimit":"8.4"}]}]},{"title":"SP263 >=1%-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"212"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","lowerLimit":"4.4","upperLimit":"5.7"},{"groupId":"OG001","value":"6.8","lowerLimit":"5.5","upperLimit":"8.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"SP263 \\>=50%-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.674","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.511","ciUpperLimit":"0.890"},{"groupIds":["OG000","OG001"],"groupDescription":"SP263 \\>=25%-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.698","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.539","ciUpperLimit":"0.904"},{"groupIds":["OG000","OG001"],"groupDescription":"SP263 \\>=1%-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.725","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.577","ciUpperLimit":"0.910"}]},{"type":"SECONDARY","title":"OS in Participants With Blood Tumor Mutational Burden (bTMB)","description":"OS is defined as the time from randomization to death from any cause.","populationDescription":"Analysis was performed for the bTMB subpopulations in the Intent-to-Treat Wild Type population.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"92"}]}],"classes":[{"title":"bTMB >=10-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","lowerLimit":"7.1","upperLimit":"16.9"},{"groupId":"OG001","value":"11.2","lowerLimit":"7.9","upperLimit":"NA","comment":"Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events."}]}]},{"title":"bTMB >=16-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","lowerLimit":"5.8","upperLimit":"NA","comment":"Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events."},{"groupId":"OG001","value":"13.9","lowerLimit":"10.8","upperLimit":"NA","comment":"Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events."}]}]},{"title":"bTMB >=20-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","lowerLimit":"5.8","upperLimit":"NA","comment":"Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events."},{"groupId":"OG001","value":"17.2","lowerLimit":"10.8","upperLimit":"NA","comment":"Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"bTMB \\>=10-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.867","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.578","ciUpperLimit":"1.301"},{"groupIds":["OG000","OG001"],"groupDescription":"bTMB \\>=16-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.748","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.414","ciUpperLimit":"1.351"},{"groupIds":["OG000","OG001"],"groupDescription":"bTMB \\>=20-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.770","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.362","ciUpperLimit":"1.638"}]},{"type":"SECONDARY","title":"Investigator-Assessed PFS in Participants With bTMB According to RECIST v1.1","description":"PFS according to RECIST v1.1 in the bTMB subpopulations.","populationDescription":"Analysis was performed for participants with bTMB \\>=10 Intent-to-treat Wild Type Population.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"92"}]}],"classes":[{"title":"bTMB >=10-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","lowerLimit":"3.1","upperLimit":"5.4"},{"groupId":"OG001","value":"5.5","lowerLimit":"2.8","upperLimit":"6.8"}]}]},{"title":"bTMB >=16-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","lowerLimit":"2.8","upperLimit":"5.7"},{"groupId":"OG001","value":"6.8","lowerLimit":"4.3","upperLimit":"11.6"}]}]},{"title":"bTMB >=20-WT Population","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","lowerLimit":"3.2","upperLimit":"6.4"},{"groupId":"OG001","value":"6.8","lowerLimit":"4.3","upperLimit":"17.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"bTMB \\>=10-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.743","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.525","ciUpperLimit":"1.052"},{"groupIds":["OG000","OG001"],"groupDescription":"bTMB \\>=16-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.553","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.331","ciUpperLimit":"0.924"},{"groupIds":["OG000","OG001"],"groupDescription":"bTMB \\>=20-WT Population","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Unstratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.560","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.295","ciUpperLimit":"1.062"}]},{"type":"SECONDARY","title":"Minimum Observed Serum Concentration (Cmin) of Atezolizumab","populationDescription":"PK analyses was based on PK observations from all randomized participants who received atezolizumab and provided at least one PK sample that was evaluable.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"micrograms per milliliter (μg/ mL)","timeFrame":"Prior to infusion (0 hour) on Day 1 of Cycles 2, 3, 4, 8, 16, and every eighth cycle thereafter, and at treatment discontinuation until data cut-off on 10 September 2018 (up to approximately 38 months) (cycle duration = 21 days)","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"256"}]}],"classes":[{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"256"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"76.7","spread":"57.6"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"215"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":"57.7"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"207"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":"90.1"}]}]},{"title":"Cycle 8 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"145"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"201","spread":"98.6"}]}]},{"title":"Cycle 16 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"213","spread":"102"}]}]},{"title":"Cycle 24 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"245","spread":"128"}]}]},{"title":"Cycle 32 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"276","spread":"110"}]}]},{"title":"Cycle 40 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"252","spread":"160"}]}]},{"title":"Cycle 48 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"555","spread":"NA","comment":"Not estimable because there is only 1 participant."}]}]},{"title":"Treatment Discontinuation Visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":"88.8"}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Serum Concentration (Cmax) of Atezolizumab","populationDescription":"PK analyses was based on PK observations from all randomized participants who received atezolizumab and provided at least one PK sample that was evaluable.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"micrograms per milliliter (μg/ mL)","timeFrame":"0 hour (predose) and 30 minutes after atezolizumab infusion on Day 1 (infusion duration = up to 1 hour)","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"270"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"411","spread":"163"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least One Adverse Event","description":"Percentage of participants with at least one adverse event.","populationDescription":"Safety analyses included treated participants, defined as randomized participants who received any amount of study treatment.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline up to until data cut-off on 8 March 2022 (up to approximately 79.5 months)","groups":[{"id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months). Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months)."},{"id":"OG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"263"},{"groupId":"OG001","value":"286"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.1"},{"groupId":"OG001","value":"92.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-therapeutic Antibodies (ATAs)","populationDescription":"The baseline ADA-evaluable population included participants who had a baseline ADA result and had received at least one dose of atezolizumab. The post-baseline ADA evaluable population included participants who had at least one post-baseline ADA result and had received at least one dose of atezolizumab.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"282"}]}],"classes":[{"title":"Baseline evaluable participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"282"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4"}]}]},{"title":"Post-baseline evaluable participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"267"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.3"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From the first study drug until the data cut-off on 8 March 2022 (up to approximately 79.5 months)","description":"All-cause mortality reported for deaths that occurred during study based on ITT, which included all randomized participants. Serious \\& other adverse events reported based on safety population, which included participants who received any amount of any study drug.","eventGroups":[{"id":"EG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)","description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).","deathsNumAffected":211,"deathsNumAtRisk":287,"seriousNumAffected":77,"seriousNumAtRisk":263,"otherNumAffected":230,"otherNumAtRisk":263},{"id":"EG001","title":"Atezolizumab","description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).","deathsNumAffected":201,"deathsNumAtRisk":285,"seriousNumAffected":97,"seriousNumAtRisk":286,"otherNumAffected":238,"otherNumAtRisk":286}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":10,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Thrombocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":286}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":286}]},{"term":"Autoimmune myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Glucocorticoid deficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Autoimmune colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Gastric haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Gastrointestinal motility disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Mechanical ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":263},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":286}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":286}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":286}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":286}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":286}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Haemophagocytic lymphohistiocytosis","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":286}]},{"term":"Immune system disorder","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":286}]},{"term":"Abscess neck","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Bronchitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":286}]},{"term":"Escherichia sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Gangrene","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":286}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":263},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":286}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Muscle abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Mycotic endophthalmitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Periodontitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Pleural infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Pneumocystis jirovecii pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":263},{"groupId":"EG001","numEvents":25,"numAffected":15,"numAtRisk":286}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Pulmonary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":263},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":286}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":263},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":286}]},{"term":"Subcutaneous abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":286}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Liver function test abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":286}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":286}]},{"term":"Tumour lysis syndrome","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Fistula","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Adenocarcinoma gastric","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Transitional cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Carotid arteriosclerosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Generalised tonic-clonic seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Neurological decompensation","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Device occlusion","organSystem":"Product Issues","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Thrombosis in device","organSystem":"Product Issues","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Ketonuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Acute pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":14,"numAffected":8,"numAtRisk":286}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":286}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":10,"numAffected":6,"numAtRisk":286}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":286}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Acute febrile neutrophilic dermatosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Autoimmune dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":286}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Extremity necrosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Hypertensive crisis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Thrombophlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Melaena","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Bacterial colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":286}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Biliary neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Laryngeal cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Pancreatic neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Bronchial obstruction","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Toxic skin eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Varicose vein","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":286}]},{"term":"Post-acute COVID-19 syndrome","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Langerhans' cell histiocytosis","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Cataract operation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Aortic aneurysm rupture","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Vein disorder","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":153,"numAffected":120,"numAtRisk":263},{"groupId":"EG001","numEvents":73,"numAffected":50,"numAtRisk":286}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":21,"numAtRisk":263},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":286}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":128,"numAffected":71,"numAtRisk":263},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":286}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":62,"numAffected":40,"numAtRisk":263},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":286}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":263},{"groupId":"EG001","numEvents":28,"numAffected":27,"numAtRisk":286}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":75,"numAffected":58,"numAtRisk":263},{"groupId":"EG001","numEvents":48,"numAffected":42,"numAtRisk":286}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":30,"numAtRisk":263},{"groupId":"EG001","numEvents":55,"numAffected":39,"numAtRisk":286}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":148,"numAffected":88,"numAtRisk":263},{"groupId":"EG001","numEvents":49,"numAffected":42,"numAtRisk":286}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":14,"numAtRisk":263},{"groupId":"EG001","numEvents":14,"numAffected":12,"numAtRisk":286}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":45,"numAffected":34,"numAtRisk":263},{"groupId":"EG001","numEvents":27,"numAffected":21,"numAtRisk":286}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":66,"numAffected":47,"numAtRisk":263},{"groupId":"EG001","numEvents":58,"numAffected":41,"numAtRisk":286}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":263},{"groupId":"EG001","numEvents":28,"numAffected":21,"numAtRisk":286}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":57,"numAffected":47,"numAtRisk":263},{"groupId":"EG001","numEvents":47,"numAffected":44,"numAtRisk":286}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":25,"numAtRisk":263},{"groupId":"EG001","numEvents":58,"numAffected":40,"numAtRisk":286}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":263},{"groupId":"EG001","numEvents":37,"numAffected":22,"numAtRisk":286}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":16,"numAtRisk":263},{"groupId":"EG001","numEvents":34,"numAffected":30,"numAtRisk":286}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":263},{"groupId":"EG001","numEvents":35,"numAffected":29,"numAtRisk":286}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":27,"numAtRisk":263},{"groupId":"EG001","numEvents":12,"numAffected":9,"numAtRisk":286}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":19,"numAtRisk":263},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":286}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":21,"numAtRisk":263},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":286}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":263},{"groupId":"EG001","numEvents":27,"numAffected":25,"numAtRisk":286}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":14,"numAtRisk":263},{"groupId":"EG001","numEvents":17,"numAffected":3,"numAtRisk":286}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":50,"numAtRisk":263},{"groupId":"EG001","numEvents":65,"numAffected":50,"numAtRisk":286}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":12,"numAtRisk":263},{"groupId":"EG001","numEvents":29,"numAffected":19,"numAtRisk":286}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":263},{"groupId":"EG001","numEvents":46,"numAffected":31,"numAtRisk":286}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":14,"numAtRisk":263},{"groupId":"EG001","numEvents":28,"numAffected":26,"numAtRisk":286}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":18,"numAtRisk":263},{"groupId":"EG001","numEvents":32,"numAffected":31,"numAtRisk":286}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":263},{"groupId":"EG001","numEvents":25,"numAffected":22,"numAtRisk":286}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":25,"numAtRisk":263},{"groupId":"EG001","numEvents":48,"numAffected":36,"numAtRisk":286}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":26,"numAtRisk":263},{"groupId":"EG001","numEvents":48,"numAffected":41,"numAtRisk":286}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":9,"numAtRisk":263},{"groupId":"EG001","numEvents":25,"numAffected":23,"numAtRisk":286}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":263},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":286}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":263},{"groupId":"EG001","numEvents":33,"numAffected":25,"numAtRisk":286}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":263},{"groupId":"EG001","numEvents":26,"numAffected":23,"numAtRisk":286}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":16,"numAtRisk":263},{"groupId":"EG001","numEvents":14,"numAffected":13,"numAtRisk":286}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":15,"numAtRisk":263},{"groupId":"EG001","numEvents":18,"numAffected":12,"numAtRisk":286}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":14,"numAtRisk":263},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":286}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":263},{"groupId":"EG001","numEvents":17,"numAffected":15,"numAtRisk":286}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann-La Roche","email":"genentech@druginfo.com","phone":"800-821-8590"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2020-02-08","uploadDate":"2021-01-26T17:07","filename":"Prot_000.pdf","size":2619504},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2019-04-02","uploadDate":"2021-01-26T17:07","filename":"SAP_001.pdf","size":1392217}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Chile","Czechia"]},"interventionBrowseModule":{"meshes":[{"id":"C000594389","term":"atezolizumab"},{"id":"D016190","term":"Carboplatin"},{"id":"D002945","term":"Cisplatin"},{"id":"D000093542","term":"Gemcitabine"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}